{ "instance": { "lvtx-20211231x20fa.htm": { "axisCustom": 6, "axisStandard": 21, "baseTaxonomies": { "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full": 677, "http://xbrl.sec.gov/dei/2021q4": 43 }, "contextCount": 273, "dts": { "calculationLink": { "local": [ "lvtx-20211231_cal.xml" ] }, "definitionLink": { "local": [ "lvtx-20211231_def.xml" ] }, "inline": { "local": [ "lvtx-20211231x20fa.htm" ] }, "labelLink": { "local": [ "lvtx-20211231_lab.xml" ] }, "presentationLink": { "local": [ "lvtx-20211231_pre.xml" ] }, "schema": { "local": [ "lvtx-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 501, "entityCount": 1, "hidden": { "http://www.lavatherapeutics.com/20211231": 3, "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full": 13, "http://xbrl.sec.gov/dei/2021q4": 5, "total": 21 }, "keyCustom": 90, "keyStandard": 215, "memberCustom": 39, "memberStandard": 30, "nsprefix": "lvtx", "nsuri": "http://www.lavatherapeutics.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.lavatherapeutics.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10301 - Disclosure - Significant accounting judgments, estimates and assumptions", "menuCat": "Notes", "order": "10", "role": "http://www.lavatherapeutics.com/role/DisclosureSignificantAccountingJudgmentsEstimatesAndAssumptions", "shortName": "Significant accounting judgments, estimates and assumptions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10401 - Disclosure - Revenue", "menuCat": "Notes", "order": "11", "role": "http://www.lavatherapeutics.com/role/DisclosureRevenue", "shortName": "Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10501 - Disclosure - Research and development expenses", "menuCat": "Notes", "order": "12", "role": "http://www.lavatherapeutics.com/role/DisclosureResearchAndDevelopmentExpenses", "shortName": "Research and development expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10601 - Disclosure - General and administrative expenses", "menuCat": "Notes", "order": "13", "role": "http://www.lavatherapeutics.com/role/DisclosureGeneralAndAdministrativeExpenses", "shortName": "General and administrative expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfBorrowingCostsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10701 - Disclosure - Interest expense, net", "menuCat": "Notes", "order": "14", "role": "http://www.lavatherapeutics.com/role/DisclosureInterestExpenseNet", "shortName": "Interest expense, net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfBorrowingCostsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10801 - Disclosure - Foreign currency exchange loss, net", "menuCat": "Notes", "order": "15", "role": "http://www.lavatherapeutics.com/role/DisclosureForeignCurrencyExchangeLossNet", "shortName": "Foreign currency exchange loss, net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10901 - Disclosure - Taxation", "menuCat": "Notes", "order": "16", "role": "http://www.lavatherapeutics.com/role/DisclosureTaxation", "shortName": "Taxation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11001 - Disclosure - Earnings per share (EPS)", "menuCat": "Notes", "order": "17", "role": "http://www.lavatherapeutics.com/role/DisclosureEarningsPerShareEps", "shortName": "Earnings per share (EPS)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11101 - Disclosure - Property and equipment", "menuCat": "Notes", "order": "18", "role": "http://www.lavatherapeutics.com/role/DisclosurePropertyAndEquipment", "shortName": "Property and equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfLeasesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11201 - Disclosure - Leases", "menuCat": "Notes", "order": "19", "role": "http://www.lavatherapeutics.com/role/DisclosureLeases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfLeasesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:RevenueFromContractsWithCustomers", "reportCount": 1, "unitRef": "Unit_Standard_USD_COOzN_LHNU2Uypi2r9KMKQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00100 - Statement - Consolidated statements of loss and other comprehensive loss", "menuCat": "Statements", "order": "2", "role": "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss", "shortName": "Consolidated statements of loss and other comprehensive loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": "-3", "lang": null, "name": "ifrs-full:OperatingExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_COOzN_LHNU2Uypi2r9KMKQ", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFinancialAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11301 - Disclosure - Investments", "menuCat": "Notes", "order": "20", "role": "http://www.lavatherapeutics.com/role/DisclosureInvestments", "shortName": "Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFinancialAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11401 - Disclosure - Cash and cash equivalents", "menuCat": "Notes", "order": "21", "role": "http://www.lavatherapeutics.com/role/DisclosureCashAndCashEquivalents", "shortName": "Cash and cash equivalents", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11501 - Disclosure - Share capital, share premium and other capital reserves", "menuCat": "Notes", "order": "22", "role": "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReserves", "shortName": "Share capital, share premium and other capital reserves", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfBorrowingsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11601 - Disclosure - Borrowings", "menuCat": "Notes", "order": "23", "role": "http://www.lavatherapeutics.com/role/DisclosureBorrowings", "shortName": "Borrowings", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfBorrowingsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11701 - Disclosure - Trade payables and other", "menuCat": "Notes", "order": "24", "role": "http://www.lavatherapeutics.com/role/DisclosureTradePayablesAndOther", "shortName": "Trade payables and other", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "lvtx:WorkingCapitalTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11801 - Disclosure - Working capital", "menuCat": "Notes", "order": "25", "role": "http://www.lavatherapeutics.com/role/DisclosureWorkingCapital", "shortName": "Working capital", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "lvtx:WorkingCapitalTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11901 - Disclosure - Share-based compensation", "menuCat": "Notes", "order": "26", "role": "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensation", "shortName": "Share-based compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "12001 - Disclosure - Related parties", "menuCat": "Notes", "order": "27", "role": "http://www.lavatherapeutics.com/role/DisclosureRelatedParties", "shortName": "Related parties", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "12101 - Disclosure - Financial instruments, risk management and capital management", "menuCat": "Notes", "order": "28", "role": "http://www.lavatherapeutics.com/role/DisclosureFinancialInstrumentsRiskManagementAndCapitalManagement", "shortName": "Financial instruments, risk management and capital management", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfContingentLiabilitiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "12201 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "29", "role": "http://www.lavatherapeutics.com/role/DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfContingentLiabilitiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "As_Of_12_31_2021_cJp_htgchkKH1MVMr5SrqQ", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:PropertyPlantAndEquipment", "reportCount": 1, "unitRef": "Unit_Standard_USD_COOzN_LHNU2Uypi2r9KMKQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00200 - Statement - Consolidated statements of financial position", "menuCat": "Statements", "order": "3", "role": "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPosition", "shortName": "Consolidated statements of financial position", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "As_Of_1_1_2020_HAX5MCEJbE-K1IUJ_GS3sg", "decimals": "-3", "lang": null, "name": "ifrs-full:PropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_COOzN_LHNU2Uypi2r9KMKQ", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "20202 - Disclosure - Summary of significant accounting policies (Policies)", "menuCat": "Policies", "order": "30", "role": "http://www.lavatherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of significant accounting policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfInformationAboutConsolidatedStructuredEntitiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30103 - Disclosure - Corporate and Company information (Tables)", "menuCat": "Tables", "order": "31", "role": "http://www.lavatherapeutics.com/role/DisclosureCorporateAndCompanyInformationTables", "shortName": "Corporate and Company information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfInformationAboutConsolidatedStructuredEntitiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "lvtx:DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30203 - Disclosure - Summary of significant accounting policies (Tables)", "menuCat": "Tables", "order": "32", "role": "http://www.lavatherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of significant accounting policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "lvtx:DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30403 - Disclosure - Revenue (Tables)", "menuCat": "Tables", "order": "33", "role": "http://www.lavatherapeutics.com/role/DisclosureRevenueTables", "shortName": "Revenue (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "lvtx:ScheduleOfResearchAndDevelopmentExpensesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30503 - Disclosure - Research and development expenses (Tables)", "menuCat": "Tables", "order": "34", "role": "http://www.lavatherapeutics.com/role/DisclosureResearchAndDevelopmentExpensesTables", "shortName": "Research and development expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "lvtx:ScheduleOfResearchAndDevelopmentExpensesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "lvtx:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30603 - Disclosure - General and administrative expenses (Tables)", "menuCat": "Tables", "order": "35", "role": "http://www.lavatherapeutics.com/role/DisclosureGeneralAndAdministrativeExpensesTables", "shortName": "General and administrative expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "lvtx:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfBorrowingCostsExplanatory", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "lvtx:DisclosureOfInterestExpensesExplanatoryTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30703 - Disclosure - Interest expense, net (Tables)", "menuCat": "Tables", "order": "36", "role": "http://www.lavatherapeutics.com/role/DisclosureInterestExpenseNetTables", "shortName": "Interest expense, net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfBorrowingCostsExplanatory", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "lvtx:DisclosureOfInterestExpensesExplanatoryTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "lvtx:DisclosureOfTaxLossCarryforwardExpiryExplanatoryTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30903 - Disclosure - Taxation (Tables)", "menuCat": "Tables", "order": "37", "role": "http://www.lavatherapeutics.com/role/DisclosureTaxationTables", "shortName": "Taxation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "lvtx:DisclosureOfTaxLossCarryforwardExpiryExplanatoryTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:EarningsPerShareExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31003 - Disclosure - Earnings per share (EPS) (Tables)", "menuCat": "Tables", "order": "38", "role": "http://www.lavatherapeutics.com/role/DisclosureEarningsPerShareEpsTables", "shortName": "Earnings per share (EPS) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:EarningsPerShareExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31103 - Disclosure - Property and equipment (Tables)", "menuCat": "Tables", "order": "39", "role": "http://www.lavatherapeutics.com/role/DisclosurePropertyAndEquipmentTables", "shortName": "Property and equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "As_Of_12_31_2018_ifrs-full_ClassesOfShareCapitalAxis_lvtx_SeriesPreferenceSharesMember_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_Sb9TJlLskkGlibA0Mys0sA", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:Equity", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_COOzN_LHNU2Uypi2r9KMKQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00300 - Statement - Consolidated statements of changes in equity", "menuCat": "Statements", "order": "4", "role": "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity", "shortName": "Consolidated statements of changes in equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "As_Of_12_31_2018_ifrs-full_ClassesOfShareCapitalAxis_lvtx_SeriesPreferenceSharesMember_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_Sb9TJlLskkGlibA0Mys0sA", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:Equity", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_COOzN_LHNU2Uypi2r9KMKQ", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfLeasesExplanatory", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31203 - Disclosure - Leases (Tables)", "menuCat": "Tables", "order": "40", "role": "http://www.lavatherapeutics.com/role/DisclosureLeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfLeasesExplanatory", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "lvtx:IfrsScheduleOfCashAndCashEquivalentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31403 - Disclosure - Cash and cash equivalents (Tables)", "menuCat": "Tables", "order": "41", "role": "http://www.lavatherapeutics.com/role/DisclosureCashAndCashEquivalentsTables", "shortName": "Cash and cash equivalents (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "lvtx:IfrsScheduleOfCashAndCashEquivalentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31503 - Disclosure - Share capital, share premium and other capital reserves (Tables)", "menuCat": "Tables", "order": "42", "role": "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesTables", "shortName": "Share capital, share premium and other capital reserves (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "lvtx:WorkingCapitalTextBlock", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31803 - Disclosure - Working capital (Tables)", "menuCat": "Tables", "order": "43", "role": "http://www.lavatherapeutics.com/role/DisclosureWorkingCapitalTables", "shortName": "Working capital (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "lvtx:WorkingCapitalTextBlock", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31903 - Disclosure - Share-based compensation (Tables)", "menuCat": "Tables", "order": "44", "role": "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationTables", "shortName": "Share-based compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "32003 - Disclosure - Related parties (Tables)", "menuCat": "Tables", "order": "45", "role": "http://www.lavatherapeutics.com/role/DisclosureRelatedPartiesTables", "shortName": "Related parties (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "32103 - Disclosure - Financial instruments, risk management and capital management (Tables)", "menuCat": "Tables", "order": "46", "role": "http://www.lavatherapeutics.com/role/DisclosureFinancialInstrumentsRiskManagementAndCapitalManagementTables", "shortName": "Financial instruments, risk management and capital management (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfInformationAboutConsolidatedStructuredEntitiesExplanatory", "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "As_Of_12_31_2021_dei_LegalEntityAxis_lvtx_LavaTherapeuticsN.v.Member_r1NC-GydlUulHj-2Lv3oLQ", "decimals": "2", "first": true, "lang": null, "name": "lvtx:ProportionOfEquityInterestHeld", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_mYfmTX8iS0uEZBFu-kQiOw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40101 - Disclosure - Corporate and Company information (Details)", "menuCat": "Details", "order": "47", "role": "http://www.lavatherapeutics.com/role/DisclosureCorporateAndCompanyInformationDetails", "shortName": "Corporate and Company information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfInformationAboutConsolidatedStructuredEntitiesExplanatory", "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "As_Of_12_31_2021_dei_LegalEntityAxis_lvtx_LavaTherapeuticsN.v.Member_r1NC-GydlUulHj-2Lv3oLQ", "decimals": "2", "first": true, "lang": null, "name": "lvtx:ProportionOfEquityInterestHeld", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_mYfmTX8iS0uEZBFu-kQiOw", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "As_Of_12_31_2021_cJp_htgchkKH1MVMr5SrqQ", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:RetainedEarnings", "reportCount": 1, "unitRef": "Unit_Standard_USD_COOzN_LHNU2Uypi2r9KMKQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40201 - Disclosure - Summary of significant accounting policies (Details)", "menuCat": "Details", "order": "48", "role": "http://www.lavatherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "shortName": "Summary of significant accounting policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "As_Of_12_31_2021_cJp_htgchkKH1MVMr5SrqQ", "decimals": "-5", "lang": null, "name": "lvtx:CashAndCashEquivalentsAndCurrentInvestments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_COOzN_LHNU2Uypi2r9KMKQ", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": "2", "first": true, "lang": null, "name": "ifrs-full:AverageEffectiveTaxRate", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_mYfmTX8iS0uEZBFu-kQiOw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40301 - Disclosure - Significant accounting judgments, estimates and assumptions (Details)", "menuCat": "Details", "order": "49", "role": "http://www.lavatherapeutics.com/role/DisclosureSignificantAccountingJudgmentsEstimatesAndAssumptionsDetails", "shortName": "Significant accounting judgments, estimates and assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": "2", "first": true, "lang": null, "name": "ifrs-full:AverageEffectiveTaxRate", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_mYfmTX8iS0uEZBFu-kQiOw", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_lvtx_IfrsSaleOfStockAxis_lvtx_IpoMember_q9ju7vnFvkGDeE38vvPnVg", "decimals": "2", "first": true, "lang": null, "name": "ifrs-full:WeightedAverageSharePrice2019", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_xvDRDQpMzECznF2mpuIe6Q", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00305 - Statement - Consolidated statements of changes in equity (Parenthetical)", "menuCat": "Statements", "order": "5", "role": "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquityParenthetical", "shortName": "Consolidated statements of changes in equity (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_lvtx_IfrsSaleOfStockAxis_lvtx_IpoMember_q9ju7vnFvkGDeE38vvPnVg", "decimals": "2", "first": true, "lang": null, "name": "ifrs-full:WeightedAverageSharePrice2019", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_xvDRDQpMzECznF2mpuIe6Q", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:RevenueFromContractsWithCustomers", "reportCount": 1, "unitRef": "Unit_Standard_USD_COOzN_LHNU2Uypi2r9KMKQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40401 - Disclosure - Revenue (Details)", "menuCat": "Details", "order": "50", "role": "http://www.lavatherapeutics.com/role/DisclosureRevenueDetails", "shortName": "Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": "-5", "lang": null, "name": "lvtx:ResearchAndLicenseAgreementRevenueUpfrontPayment", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_COOzN_LHNU2Uypi2r9KMKQ", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "lvtx:ScheduleOfResearchAndDevelopmentExpensesTableTextBlock", "ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": "-3", "first": true, "lang": null, "name": "lvtx:ResearchAndDevelopmentLicenseExpenses", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_COOzN_LHNU2Uypi2r9KMKQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40501 - Disclosure - Research and development expenses (Details)", "menuCat": "Details", "order": "51", "role": "http://www.lavatherapeutics.com/role/DisclosureResearchAndDevelopmentExpensesDetails", "shortName": "Research and development expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "lvtx:ScheduleOfResearchAndDevelopmentExpensesTableTextBlock", "ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": "-3", "first": true, "lang": null, "name": "lvtx:ResearchAndDevelopmentLicenseExpenses", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_COOzN_LHNU2Uypi2r9KMKQ", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "lvtx:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock", "ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": "-3", "first": true, "lang": null, "name": "lvtx:GeneralAndAdministrativeExpensePersonnelRelatedExpenses", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_COOzN_LHNU2Uypi2r9KMKQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40601 - Disclosure - General and administrative expenses (Details)", "menuCat": "Details", "order": "52", "role": "http://www.lavatherapeutics.com/role/DisclosureGeneralAndAdministrativeExpensesDetails", "shortName": "General and administrative expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "lvtx:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock", "ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": "-3", "first": true, "lang": null, "name": "lvtx:GeneralAndAdministrativeExpensePersonnelRelatedExpenses", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_COOzN_LHNU2Uypi2r9KMKQ", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "lvtx:DisclosureOfInterestExpensesExplanatoryTableTextBlock", "ifrs-full:DisclosureOfBorrowingCostsExplanatory", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:InterestExpenseOnBorrowings", "reportCount": 1, "unitRef": "Unit_Standard_USD_COOzN_LHNU2Uypi2r9KMKQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40701 - Disclosure - Interest expense, net (Details)", "menuCat": "Details", "order": "53", "role": "http://www.lavatherapeutics.com/role/DisclosureInterestExpenseNetDetails", "shortName": "Interest expense, net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "lvtx:DisclosureOfInterestExpensesExplanatoryTableTextBlock", "ifrs-full:DisclosureOfBorrowingCostsExplanatory", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": "-3", "lang": null, "name": "ifrs-full:InterestExpenseOnLeaseLiabilities", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_COOzN_LHNU2Uypi2r9KMKQ", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": "-5", "first": true, "lang": null, "name": "ifrs-full:NetForeignExchangeLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_COOzN_LHNU2Uypi2r9KMKQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40801 - Disclosure - Foreign currency exchange loss, net (Details)", "menuCat": "Details", "order": "54", "role": "http://www.lavatherapeutics.com/role/DisclosureForeignCurrencyExchangeLossNetDetails", "shortName": "Foreign currency exchange loss, net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": "-5", "first": true, "lang": null, "name": "ifrs-full:NetForeignExchangeLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_COOzN_LHNU2Uypi2r9KMKQ", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:IncomeTaxExpenseContinuingOperations", "reportCount": 1, "unitRef": "Unit_Standard_USD_COOzN_LHNU2Uypi2r9KMKQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40901 - Disclosure - Taxation (Details)", "menuCat": "Details", "order": "55", "role": "http://www.lavatherapeutics.com/role/DisclosureTaxationDetails", "shortName": "Taxation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_ifrs-full_GeographicalAreasAxis_country_NL_wWoZGDrK4kab9nki9PXMTw", "decimals": "0", "lang": null, "name": "ifrs-full:IncomeTaxExpenseContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_COOzN_LHNU2Uypi2r9KMKQ", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "lvtx:DisclosureOfTaxLossCarryforwardExpiryExplanatoryTableTextBlock", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "As_Of_12_31_2021_cJp_htgchkKH1MVMr5SrqQ", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised", "reportCount": 1, "unitRef": "Unit_Standard_USD_COOzN_LHNU2Uypi2r9KMKQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40902 - Disclosure - Taxation - Tax-losses carry forward (Details)", "menuCat": "Details", "order": "56", "role": "http://www.lavatherapeutics.com/role/DisclosureTaxationTaxLossesCarryForwardDetails", "shortName": "Taxation - Tax-losses carry forward (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "As_Of_12_31_2021_cJp_htgchkKH1MVMr5SrqQ", "decimals": "2", "lang": null, "name": "lvtx:InnovationBoxTaxRatePercentagePercentage", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_mYfmTX8iS0uEZBFu-kQiOw", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ProfitLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_COOzN_LHNU2Uypi2r9KMKQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41001 - Disclosure - Earnings per share (EPS) (Details)", "menuCat": "Details", "order": "57", "role": "http://www.lavatherapeutics.com/role/DisclosureEarningsPerShareEpsDetails", "shortName": "Earnings per share (EPS) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R58": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "As_Of_12_31_2020__TTR7OKxxkGELj2tcKaekw", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:PropertyPlantAndEquipment", "reportCount": 1, "unitRef": "Unit_Standard_USD_COOzN_LHNU2Uypi2r9KMKQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41101 - Disclosure - Property and equipment (Details)", "menuCat": "Details", "order": "58", "role": "http://www.lavatherapeutics.com/role/DisclosurePropertyAndEquipmentDetails", "shortName": "Property and equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "As_Of_12_31_2019_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_AKazCotCm0-X3UF8qCMezQ", "decimals": "-3", "lang": null, "name": "ifrs-full:PropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_COOzN_LHNU2Uypi2r9KMKQ", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "As_Of_12_31_2020__TTR7OKxxkGELj2tcKaekw", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:RightofuseAssets", "reportCount": 1, "unitRef": "Unit_Standard_USD_COOzN_LHNU2Uypi2r9KMKQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41201 - Disclosure - Leases (Details)", "menuCat": "Details", "order": "59", "role": "http://www.lavatherapeutics.com/role/DisclosureLeasesDetails", "shortName": "Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "As_Of_12_31_2019_rVaKYZy-d02ascwflZp3WQ", "decimals": "-3", "lang": null, "name": "ifrs-full:RightofuseAssets", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_COOzN_LHNU2Uypi2r9KMKQ", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ProfitLossBeforeTax", "reportCount": 1, "unitRef": "Unit_Standard_USD_COOzN_LHNU2Uypi2r9KMKQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00400 - Statement - Consolidated statements of cash flows", "menuCat": "Statements", "order": "6", "role": "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows", "shortName": "Consolidated statements of cash flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": "-3", "lang": null, "name": "ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_COOzN_LHNU2Uypi2r9KMKQ", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "lvtx:DisclosureOfMaturityAnalysisOfLeasePaymentsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "As_Of_12_31_2021_cJp_htgchkKH1MVMr5SrqQ", "decimals": "-3", "first": true, "lang": null, "name": "lvtx:UndiscountedLeaseLiabilityPaymentsDue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_COOzN_LHNU2Uypi2r9KMKQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41202 - Disclosure - Leases - Maturities of lease liabilities (Details)", "menuCat": "Details", "order": "60", "role": "http://www.lavatherapeutics.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails", "shortName": "Leases - Maturities of lease liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "lvtx:DisclosureOfMaturityAnalysisOfLeasePaymentsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "As_Of_12_31_2021_cJp_htgchkKH1MVMr5SrqQ", "decimals": "-3", "first": true, "lang": null, "name": "lvtx:UndiscountedLeaseLiabilityPaymentsDue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_COOzN_LHNU2Uypi2r9KMKQ", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfFinancialAssetsExplanatory", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "As_Of_12_31_2021_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_1g5trDDoz0i5imFeHd9-zQ", "decimals": "-5", "first": true, "lang": null, "name": "ifrs-full:FinancialAssets", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_COOzN_LHNU2Uypi2r9KMKQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41301 - Disclosure - Investments (Details)", "menuCat": "Details", "order": "61", "role": "http://www.lavatherapeutics.com/role/DisclosureInvestmentsDetails", "shortName": "Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfFinancialAssetsExplanatory", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "As_Of_12_31_2021_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_1g5trDDoz0i5imFeHd9-zQ", "decimals": "-5", "first": true, "lang": null, "name": "ifrs-full:FinancialAssets", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_COOzN_LHNU2Uypi2r9KMKQ", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "lvtx:IfrsScheduleOfCashAndCashEquivalentsTableTextBlock", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "As_Of_12_31_2021_cJp_htgchkKH1MVMr5SrqQ", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_COOzN_LHNU2Uypi2r9KMKQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41401 - Disclosure - Cash and cash equivalents (Details)", "menuCat": "Details", "order": "62", "role": "http://www.lavatherapeutics.com/role/DisclosureCashAndCashEquivalentsDetails", "shortName": "Cash and cash equivalents (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "lvtx:IfrsScheduleOfCashAndCashEquivalentsTableTextBlock", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "As_Of_12_31_2021_cJp_htgchkKH1MVMr5SrqQ", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_COOzN_LHNU2Uypi2r9KMKQ", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "As_Of_12_31_2021_cJp_htgchkKH1MVMr5SrqQ", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:NumberOfSharesAuthorised", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_JUzX1zhMe0axjHCXSJsKfw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41501 - Disclosure - Share capital, share premium and other capital reserves - Summary (Details)", "menuCat": "Details", "order": "63", "role": "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesSummaryDetails", "shortName": "Share capital, share premium and other capital reserves - Summary (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "As_Of_12_31_2021_cJp_htgchkKH1MVMr5SrqQ", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:NumberOfSharesAuthorised", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_JUzX1zhMe0axjHCXSJsKfw", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ProceedsFromIssueOfPreferenceShares", "reportCount": 1, "unitRef": "Unit_Standard_USD_COOzN_LHNU2Uypi2r9KMKQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41502 - Disclosure - Share capital, share premium and other capital reserves - Preference share (Details)", "menuCat": "Details", "order": "64", "role": "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesPreferenceShareDetails", "shortName": "Share capital, share premium and other capital reserves - Preference share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_3_17_2021_To_3_17_2021_bTJonsjzGUS3eq16VVQdWg", "decimals": "0", "lang": null, "name": "lvtx:StockSplitConversionRatio", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_mYfmTX8iS0uEZBFu-kQiOw", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ProceedsFromIssueOfOrdinaryShares", "reportCount": 1, "unitRef": "Unit_Standard_USD_COOzN_LHNU2Uypi2r9KMKQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41503 - Disclosure - Share capital, share premium and other capital reserves - Common shares (Details)", "menuCat": "Details", "order": "65", "role": "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesCommonSharesDetails", "shortName": "Share capital, share premium and other capital reserves - Common shares (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_6_2_2021_To_6_2_2021_EmQIRZJhjESvaqWQzCT0hA", "decimals": "INF", "lang": null, "name": "lvtx:SharesIssuedInLieuOfLicenseLiabilities", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_JUzX1zhMe0axjHCXSJsKfw", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "lvtx:ScheduleOfMajorShareholdersOnNonDilutedBasisTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": "3", "first": true, "lang": null, "name": "lvtx:ShareholdingPercentage", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_mYfmTX8iS0uEZBFu-kQiOw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41504 - Disclosure - Share capital, share premium and other capital reserves - Major shareholders (Details)", "menuCat": "Details", "order": "66", "role": "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesMajorShareholdersDetails", "shortName": "Share capital, share premium and other capital reserves - Major shareholders (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "lvtx:ScheduleOfMajorShareholdersOnNonDilutedBasisTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": "3", "first": true, "lang": null, "name": "lvtx:ShareholdingPercentage", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_mYfmTX8iS0uEZBFu-kQiOw", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "As_Of_12_31_2021_cJp_htgchkKH1MVMr5SrqQ", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:LongtermBorrowings", "reportCount": 1, "unitRef": "Unit_Standard_USD_COOzN_LHNU2Uypi2r9KMKQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41601 - Disclosure - Borrowings (Details)", "menuCat": "Details", "order": "67", "role": "http://www.lavatherapeutics.com/role/DisclosureBorrowingsDetails", "shortName": "Borrowings (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfBorrowingsExplanatory", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "As_Of_12_31_2021_ifrs-full_BorrowingsByNameAxis_lvtx_InnovationCreditMember_GJzMISMYxEO8ah--fLKcXw", "decimals": "-5", "lang": null, "name": "ifrs-full:LongtermBorrowings", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_COOzN_LHNU2Uypi2r9KMKQ", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "As_Of_12_31_2021_cJp_htgchkKH1MVMr5SrqQ", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:TradeAndOtherCurrentPayables", "reportCount": 1, "unitRef": "Unit_Standard_USD_COOzN_LHNU2Uypi2r9KMKQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41701 - Disclosure - Trade payables and other (Details)", "menuCat": "Details", "order": "68", "role": "http://www.lavatherapeutics.com/role/DisclosureTradePayablesAndOtherDetails", "shortName": "Trade payables and other (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_gykmKjO950eqwORG5v7uCw", "decimals": null, "lang": "en-US", "name": "lvtx:AverageCreditPeriodOnDomesticPurchasesOfCertainGoods", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory", "lvtx:WorkingCapitalTextBlock", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "As_Of_12_31_2021_cJp_htgchkKH1MVMr5SrqQ", "decimals": "-3", "first": true, "lang": null, "name": "lvtx:PrepaidProjectExpenses", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_COOzN_LHNU2Uypi2r9KMKQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41801 - Disclosure - Working capital - Prepaid expenses and other current assets (Details)", "menuCat": "Details", "order": "69", "role": "http://www.lavatherapeutics.com/role/DisclosureWorkingCapitalPrepaidExpensesAndOtherCurrentAssetsDetails", "shortName": "Working capital - Prepaid expenses and other current assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory", "lvtx:WorkingCapitalTextBlock", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "As_Of_12_31_2021_cJp_htgchkKH1MVMr5SrqQ", "decimals": "-3", "first": true, "lang": null, "name": "lvtx:PrepaidProjectExpenses", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_COOzN_LHNU2Uypi2r9KMKQ", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": "INF", "first": true, "lang": null, "name": "lvtx:SharesIssuedInLieuOfLicenseLiability", "reportCount": 1, "unitRef": "Unit_Standard_shares_JUzX1zhMe0axjHCXSJsKfw", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00405 - Statement - Consolidated statements of cash flows (Parenthetical)", "menuCat": "Statements", "order": "7", "role": "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical", "shortName": "Consolidated statements of cash flows (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R70": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "lvtx:ScheduleOfAccruedExpensesAndOtherLiabilitiesTableTextBlock", "lvtx:WorkingCapitalTextBlock", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "As_Of_12_31_2021_cJp_htgchkKH1MVMr5SrqQ", "decimals": "-3", "first": true, "lang": null, "name": "lvtx:ResearchAndDevelopmentExternalProjectCostsCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_COOzN_LHNU2Uypi2r9KMKQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41802 - Disclosure - Working capital - Accrued expenses and other current liabilities (Details)", "menuCat": "Details", "order": "70", "role": "http://www.lavatherapeutics.com/role/DisclosureWorkingCapitalAccruedExpensesAndOtherCurrentLiabilitiesDetails", "shortName": "Working capital - Accrued expenses and other current liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "lvtx:ScheduleOfAccruedExpensesAndOtherLiabilitiesTableTextBlock", "lvtx:WorkingCapitalTextBlock", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "As_Of_12_31_2021_cJp_htgchkKH1MVMr5SrqQ", "decimals": "-3", "first": true, "lang": null, "name": "lvtx:ResearchAndDevelopmentExternalProjectCostsCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_COOzN_LHNU2Uypi2r9KMKQ", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "As_Of_12_31_2020_lvtx_IfrsPlanNameAxis_lvtx_StockOptionPlan2018Member_nNM6i998iEmIAnnVA_DPGg", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:NumberOfOutstandingShareOptions", "reportCount": 1, "unitRef": "Unit_Standard_Option_5__GdHlEKUa8pJ4Go0zSjw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41901 - Disclosure - Share-based compensation - Number of option and exercise price (Details)", "menuCat": "Details", "order": "71", "role": "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationNumberOfOptionAndExercisePriceDetails", "shortName": "Share-based compensation - Number of option and exercise price (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "As_Of_12_31_2019_lvtx_IfrsPlanNameAxis_lvtx_StockOptionPlan2018Member_nGB4djgklkiZKoJfzlNwwA", "decimals": "INF", "lang": null, "name": "ifrs-full:NumberOfOutstandingShareOptions", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_Option_5__GdHlEKUa8pJ4Go0zSjw", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_ifrs-full_GeographicalAreasAxis_country_NL_wWoZGDrK4kab9nki9PXMTw", "decimals": "4", "first": true, "lang": null, "name": "ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_mYfmTX8iS0uEZBFu-kQiOw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41902 - Disclosure - Share-based compensation - Fair value measurement (Details)", "menuCat": "Details", "order": "72", "role": "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationFairValueMeasurementDetails", "shortName": "Share-based compensation - Fair value measurement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_ifrs-full_GeographicalAreasAxis_country_NL_wWoZGDrK4kab9nki9PXMTw", "decimals": "4", "first": true, "lang": null, "name": "ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_mYfmTX8iS0uEZBFu-kQiOw", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": "-5", "first": true, "lang": null, "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_COOzN_LHNU2Uypi2r9KMKQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41903 - Disclosure - Share-based compensation - Narratives (Details)", "menuCat": "Details", "order": "73", "role": "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationNarrativesDetails", "shortName": "Share-based compensation - Narratives (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": "-5", "first": true, "lang": null, "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_COOzN_LHNU2Uypi2r9KMKQ", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_COOzN_LHNU2Uypi2r9KMKQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "42001 - Disclosure - Related parties - Key management compensation (Details)", "menuCat": "Details", "order": "74", "role": "http://www.lavatherapeutics.com/role/DisclosureRelatedPartiesKeyManagementCompensationDetails", "shortName": "Related parties - Key management compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_COOzN_LHNU2Uypi2r9KMKQ", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": "-3", "first": true, "lang": null, "name": "lvtx:DirectorsBoardFees", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_COOzN_LHNU2Uypi2r9KMKQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "42002 - Disclosure - Related parties - Director and shareholder compensation (Details)", "menuCat": "Details", "order": "75", "role": "http://www.lavatherapeutics.com/role/DisclosureRelatedPartiesDirectorAndShareholderCompensationDetails", "shortName": "Related parties - Director and shareholder compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": "-3", "first": true, "lang": null, "name": "lvtx:DirectorsBoardFees", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_COOzN_LHNU2Uypi2r9KMKQ", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "As_Of_12_31_2021_cJp_htgchkKH1MVMr5SrqQ", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CashAndCashEquivalents", "reportCount": 1, "unitRef": "Unit_Standard_USD_COOzN_LHNU2Uypi2r9KMKQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "42101 - Disclosure - Financial instruments, risk management and capital management (Details)", "menuCat": "Details", "order": "76", "role": "http://www.lavatherapeutics.com/role/DisclosureFinancialInstrumentsRiskManagementAndCapitalManagementDetails", "shortName": "Financial instruments, risk management and capital management (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "As_Of_12_31_2021_ifrs-full_TypesOfRisksAxis_ifrs-full_CreditRiskMember_kC627cw8Dka99N1ttBbidA", "decimals": "-5", "lang": null, "name": "ifrs-full:CashAndCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_COOzN_LHNU2Uypi2r9KMKQ", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfContingentLiabilitiesExplanatory", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "As_Of_12_31_2021_cJp_htgchkKH1MVMr5SrqQ", "decimals": "-5", "first": true, "lang": null, "name": "lvtx:LeaseCommitments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_COOzN_LHNU2Uypi2r9KMKQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "42201 - Disclosure - Commitments and Contingencies (Details)", "menuCat": "Details", "order": "77", "role": "http://www.lavatherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfContingentLiabilitiesExplanatory", "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "As_Of_12_31_2021_cJp_htgchkKH1MVMr5SrqQ", "decimals": "-5", "first": true, "lang": null, "name": "lvtx:LeaseCommitments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_COOzN_LHNU2Uypi2r9KMKQ", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10101 - Disclosure - Corporate and Company information", "menuCat": "Notes", "order": "8", "role": "http://www.lavatherapeutics.com/role/DisclosureCorporateAndCompanyInformation", "shortName": "Corporate and Company information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10201 - Disclosure - Summary of significant accounting policies", "menuCat": "Notes", "order": "9", "role": "http://www.lavatherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "Summary of significant accounting policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "lvtx-20211231x20fa.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_qf_iMlPht0e-mpcZf_4Cfg", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 70, "tag": { "country_NL": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NL" } } }, "localname": "NL", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationFairValueMeasurementDetails", "http://www.lavatherapeutics.com/role/DisclosureTaxationDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "US" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "dei_AddressTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.", "label": "Address Type [Domain]" } } }, "localname": "AddressTypeDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lavatherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lavatherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r229", "r230", "r231" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lavatherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r229", "r230", "r231" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lavatherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r229", "r230", "r231" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lavatherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_BusinessContactMember": { "auth_ref": [ "r230", "r231" ], "lang": { "en-us": { "role": { "documentation": "Business contact for the entity", "label": "Business Contact [Member]" } } }, "localname": "BusinessContactMember", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lavatherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dei_ContactPersonnelEmailAddress": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Email address of contact personnel.", "label": "Contact Personnel Email Address" } } }, "localname": "ContactPersonnelEmailAddress", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lavatherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_ContactPersonnelName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of contact personnel", "label": "Contact Personnel Name" } } }, "localname": "ContactPersonnelName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lavatherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Document and Entity Information [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lavatherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r230" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lavatherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r229", "r230", "r231" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lavatherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lavatherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lavatherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lavatherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lavatherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lavatherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r225" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lavatherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r230" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lavatherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r232" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lavatherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lavatherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lavatherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Adress Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lavatherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lavatherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lavatherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lavatherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lavatherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityAddressesAddressTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Addresses, Address Type [Axis]" } } }, "localname": "EntityAddressesAddressTypeAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lavatherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r227" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lavatherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lavatherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lavatherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureCorporateAndCompanyInformationDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r227" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lavatherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r235" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lavatherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lavatherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r227" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lavatherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lavatherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r233" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lavatherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r227" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lavatherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r227" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lavatherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lavatherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r234" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lavatherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r229", "r230", "r231" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lavatherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureCorporateAndCompanyInformationDetails" ], "xbrltype": "stringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r226" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lavatherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r228" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lavatherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lavatherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember": { "auth_ref": [ "r38", "r45", "r72", "r77", "r80" ], "lang": { "en": { "role": { "documentation": "This member stands for accumulated depreciation, amortisation and impairment. [Refer: Impairment loss; Depreciation and amortisation expense]" } }, "en-us": { "role": { "label": "Accumulated depreciation, amortisation and impairment [member]" } } }, "localname": "AccumulatedDepreciationAmortisationAndImpairmentMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_AdditionalPaidinCapital": { "auth_ref": [ "r242" ], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPositions": { "order": 6.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value and amounts received from other transactions involving the entity's stock or stockholders." } }, "en-us": { "role": { "label": "Additional paid-in capital.", "terseLabel": "Additional paid in capital" } } }, "localname": "AdditionalPaidinCapital", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesSummaryDetails", "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdditionalPaidinCapitalMember": { "auth_ref": [ "r238" ], "lang": { "en": { "role": { "documentation": "This member stands for amounts received from issuance of the entity's shares in excess of nominal value and amounts received from other transactions involving the entity's stock or stockholders." } }, "en-us": { "role": { "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidinCapitalMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": { "auth_ref": [ "r39" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]" } }, "en-us": { "role": { "label": "Additions other than through business combinations, property, plant and equipment", "terseLabel": "Additions" } } }, "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdditionsToRightofuseAssets": { "auth_ref": [ "r122" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of additions to right-of-use assets. [Refer: Right-of-use assets]" } }, "en-us": { "role": { "label": "Additions to right-of-use assets", "terseLabel": "Additions" } } }, "localname": "AdditionsToRightofuseAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureLeasesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustedWeightedAverageShares": { "auth_ref": [ "r67" ], "lang": { "en": { "role": { "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average number of ordinary shares used in calculating diluted earnings per share", "terseLabel": "Weighted average common shares outstanding, diluted" } } }, "localname": "AdjustedWeightedAverageShares", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureEarningsPerShareEpsDetails", "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "xbrltype": "sharesItemType" }, "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets": { "auth_ref": [ "r251" ], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for decrease (increase) in other assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other assets; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for decrease (increase) in other assets", "terseLabel": "Other assets" } } }, "localname": "AdjustmentsForDecreaseIncreaseInOtherAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables": { "auth_ref": [ "r251" ], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for decrease (increase) in trade and other receivables", "terseLabel": "Receivables and other" } } }, "localname": "AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense": { "auth_ref": [ "r250" ], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for depreciation and amortisation expense", "terseLabel": "Depreciation and amortization of non-current assets" } } }, "localname": "AdjustmentsForDepreciationAndAmortisationExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForIncomeTaxExpense": { "auth_ref": [ "r85" ], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for income tax expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for income tax expense", "terseLabel": "Income tax expense" } } }, "localname": "AdjustmentsForIncomeTaxExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities": { "auth_ref": [ "r249" ], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for the increase (decrease) in contract liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Contract liabilities; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for increase (decrease) in contract liabilities", "terseLabel": "Deferred revenue" } } }, "localname": "AdjustmentsForIncreaseDecreaseInContractLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities": { "auth_ref": [ "r251" ], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for increase (decrease) in other liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other liabilities; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for increase (decrease) in other liabilities", "terseLabel": "Other liabilities" } } }, "localname": "AdjustmentsForIncreaseDecreaseInOtherLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": { "auth_ref": [ "r251" ], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for increase (decrease) in trade and other payables", "terseLabel": "Trade accounts payable and other" } } }, "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile profit (loss) [abstract]", "terseLabel": "Adjusted for:" } } }, "localname": "AdjustmentsForReconcileProfitLossAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "ifrs-full_AdjustmentsForSharebasedPayments": { "auth_ref": [ "r250" ], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for share-based payments", "terseLabel": "Share-based compensation expense" } } }, "localname": "AdjustmentsForSharebasedPayments", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains": { "auth_ref": [ "r202", "r250" ], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for unrealised foreign exchange losses (gains)", "terseLabel": "Foreign currency exchange loss, net" } } }, "localname": "AdjustmentsForUnrealisedForeignExchangeLossesGains", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AggregatedMeasurementMember": { "auth_ref": [ "r75", "r79", "r105" ], "lang": { "en": { "role": { "documentation": "This member stands for all types of measurement. It also represents the standard value for the 'Measurement' axis if no other member is used." } }, "en-us": { "role": { "label": "Aggregated measurement [member]" } } }, "localname": "AggregatedMeasurementMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureInvestmentsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_AggregatedTimeBandsMember": { "auth_ref": [ "r13", "r115", "r125", "r126", "r146", "r173", "r174", "r175", "r181", "r193", "r215", "r216" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used." } }, "en-us": { "role": { "label": "Aggregated time bands [member]" } } }, "localname": "AggregatedTimeBandsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_AmountsPayableRelatedPartyTransactions": { "auth_ref": [ "r55", "r58" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amounts payable resulting from related party transactions. [Refer: Related parties [member]]" } }, "en-us": { "role": { "label": "Amounts payable, related party transactions", "terseLabel": "Related party expenses" } } }, "localname": "AmountsPayableRelatedPartyTransactions", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureRelatedPartiesDirectorAndShareholderCompensationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ApplicableTaxRate": { "auth_ref": [ "r32" ], "lang": { "en": { "role": { "documentation": "The applicable income tax rate." } }, "en-us": { "role": { "label": "Applicable tax rate", "terseLabel": "General headline rate" } } }, "localname": "ApplicableTaxRate", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureSignificantAccountingJudgmentsEstimatesAndAssumptionsDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_Assets": { "auth_ref": [ "r11", "r105", "r106", "r107", "r166", "r168" ], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPositions": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } }, "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_AtFairValueMember": { "auth_ref": [ "r75", "r79", "r105" ], "lang": { "en": { "role": { "documentation": "This member stands for measurement based on fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date." } }, "en-us": { "role": { "label": "Fair value" } } }, "localname": "AtFairValueMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureInvestmentsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_AverageEffectiveTaxRate": { "auth_ref": [ "r32" ], "lang": { "en": { "role": { "documentation": "The tax expense (income) divided by the accounting profit. [Refer: Accounting profit]" } }, "en-us": { "role": { "label": "Average effective tax rate", "terseLabel": "Income tax rate" } } }, "localname": "AverageEffectiveTaxRate", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureSignificantAccountingJudgmentsEstimatesAndAssumptionsDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_BalancesWithBanks": { "auth_ref": [ "r252" ], "calculation": { "http://www.lavatherapeutics.com/role/DisclosureCashAndCashEquivalentsDetails": { "order": 2.0, "parentTag": "ifrs-full_CashAndCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of cash balances held at banks." } }, "en-us": { "role": { "label": "Balances with banks", "terseLabel": "Current bank accounts" } } }, "localname": "BalancesWithBanks", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureCashAndCashEquivalentsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_BasicEarningsLossPerShare": { "auth_ref": [ "r65", "r66" ], "lang": { "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)." } }, "en-us": { "role": { "label": "Basic earnings (loss) per share", "terseLabel": "Loss per share, basic" } } }, "localname": "BasicEarningsLossPerShare", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureEarningsPerShareEpsDetails", "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "ifrs-full_BorrowingsByNameAxis": { "auth_ref": [ "r253" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Borrowings by name [axis]" } } }, "localname": "BorrowingsByNameAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureBorrowingsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_BorrowingsByNameMember": { "auth_ref": [ "r253" ], "lang": { "en": { "role": { "documentation": "This member stands for all borrowings when disaggregated by name. It also represents the standard value for the 'Borrowings by name' axis if no other member is used. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Borrowings by name [member]" } } }, "localname": "BorrowingsByNameMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureBorrowingsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_BorrowingsInterestRate": { "auth_ref": [ "r253" ], "lang": { "en": { "role": { "documentation": "The interest rate on borrowings. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Borrowings, interest rate", "terseLabel": "Stated interest rate" } } }, "localname": "BorrowingsInterestRate", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureBorrowingsDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_BottomOfRangeMember": { "auth_ref": [ "r109", "r138", "r175", "r206", "r208", "r253" ], "lang": { "en": { "role": { "documentation": "This member stands for the bottom of a range." } }, "en-us": { "role": { "label": "Bottom of range" } } }, "localname": "BottomOfRangeMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureRelatedPartiesDirectorAndShareholderCompensationDetails", "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationFairValueMeasurementDetails", "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationNarrativesDetails", "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationNumberOfOptionAndExercisePriceDetails", "http://www.lavatherapeutics.com/role/DisclosureTradePayablesAndOtherDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": { "auth_ref": [ "r38", "r42", "r72", "r73", "r76", "r77", "r78", "r79", "r80", "r143", "r151", "r152", "r255", "r256" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]" } } }, "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_CarryingAmountMember": { "auth_ref": [ "r42", "r73", "r76", "r78", "r79", "r143", "r151", "r152", "r223", "r224" ], "lang": { "en": { "role": { "documentation": "This member stands for the amount at which an asset is recognised in the statement of financial position (after deducting any accumulated depreciation or amortisation and accumulated impairment losses). It also represents the standard value for the 'Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount' axis if no other member is used. [Refer: Depreciation and amortisation expense; Impairment loss]" } }, "en-us": { "role": { "label": "Carrying amount [member]" } } }, "localname": "CarryingAmountMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_CashAndCashEquivalents": { "auth_ref": [ "r9", "r86", "r100" ], "calculation": { "http://www.lavatherapeutics.com/role/DisclosureCashAndCashEquivalentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPositions": { "order": 5.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]" } }, "en-us": { "role": { "label": "Cash and cash equivalents.", "periodEndLabel": "Cash and cash equivalents at end of year", "periodStartLabel": "Cash and cash equivalents at the beginning of year", "terseLabel": "Cash and cash equivalents", "totalLabel": "Total" } } }, "localname": "CashAndCashEquivalents", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureCashAndCashEquivalentsDetails", "http://www.lavatherapeutics.com/role/DisclosureFinancialInstrumentsRiskManagementAndCapitalManagementDetails", "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and cash equivalent" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_CashFlowsFromUsedInFinancingActivities": { "auth_ref": [ "r81", "r88" ], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity." } }, "en-us": { "role": { "label": "Cash flows from (used in) financing activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "CashFlowsFromUsedInFinancingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) financing activities [abstract]", "terseLabel": "Cash flows from financing activities" } } }, "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "ifrs-full_CashFlowsFromUsedInInvestingActivities": { "auth_ref": [ "r81", "r88" ], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents." } }, "en-us": { "role": { "label": "Cash flows from (used in) investing activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "CashFlowsFromUsedInInvestingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) investing activities [abstract]", "terseLabel": "Cash flows from investing activities" } } }, "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "ifrs-full_CashFlowsFromUsedInOperatingActivities": { "auth_ref": [ "r81", "r88" ], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0 } }, "lang": { "en": { "role": { "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]" } }, "en-us": { "role": { "label": "Cash flows from (used in) operating activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "CashFlowsFromUsedInOperatingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) operating activities [abstract]", "terseLabel": "Cash flows from operating activities" } } }, "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "ifrs-full_CashOutflowForLeases": { "auth_ref": [ "r121" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for leases." } }, "en-us": { "role": { "label": "Cash outflow for leases", "terseLabel": "Cash outflows related to leases" } } }, "localname": "CashOutflowForLeases", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CategoriesOfFinancialAssetsAxis": { "auth_ref": [ "r161" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Categories of financial assets [axis]" } } }, "localname": "CategoriesOfFinancialAssetsAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureFinancialInstrumentsRiskManagementAndCapitalManagementDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_CategoriesOfFinancialLiabilitiesAxis": { "auth_ref": [ "r161" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Categories of financial liabilities [axis]" } } }, "localname": "CategoriesOfFinancialLiabilitiesAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureFinancialInstrumentsRiskManagementAndCapitalManagementDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfAssetsAxis": { "auth_ref": [ "r69", "r70", "r108", "r124" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of assets [axis]" } } }, "localname": "ClassesOfAssetsAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureInvestmentsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfAssetsMember": { "auth_ref": [ "r69", "r108", "r124" ], "lang": { "en": { "role": { "documentation": "This member stands for a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of assets' axis if no other member is used." } }, "en-us": { "role": { "label": "Assets [member]" } } }, "localname": "ClassesOfAssetsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureInvestmentsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ClassesOfFinancialAssetsAxis": { "auth_ref": [ "r156", "r157", "r172", "r182", "r183", "r184" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of financial assets [axis]" } } }, "localname": "ClassesOfFinancialAssetsAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureFinancialInstrumentsRiskManagementAndCapitalManagementDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfFinancialLiabilitiesAxis": { "auth_ref": [ "r156", "r157", "r172", "r183" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of financial liabilities [axis]" } } }, "localname": "ClassesOfFinancialLiabilitiesAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureFinancialInstrumentsRiskManagementAndCapitalManagementDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": { "auth_ref": [ "r43" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of property, plant and equipment [axis]" } } }, "localname": "ClassesOfPropertyPlantAndEquipmentAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosurePropertyAndEquipmentDetails", "http://www.lavatherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfShareCapitalAxis": { "auth_ref": [ "r24" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of share capital [axis]" } } }, "localname": "ClassesOfShareCapitalAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesCommonSharesDetails", "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesPreferenceShareDetails", "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesSummaryDetails", "http://www.lavatherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity", "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquityParenthetical" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfShareCapitalMember": { "auth_ref": [ "r24" ], "lang": { "en": { "role": { "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used." } }, "en-us": { "role": { "label": "Share capital [member]" } } }, "localname": "ClassesOfShareCapitalMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesCommonSharesDetails", "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesPreferenceShareDetails", "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesSummaryDetails", "http://www.lavatherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity", "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquityParenthetical" ], "xbrltype": "domainItemType" }, "ifrs-full_CommunicationAndNetworkEquipmentMember": { "auth_ref": [ "r246" ], "lang": { "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing communications and network equipment. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Information and communication equipment (ICT)" } } }, "localname": "CommunicationAndNetworkEquipmentMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosurePropertyAndEquipmentDetails", "http://www.lavatherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ComponentsOfEquityAxis": { "auth_ref": [ "r3" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Components of equity [axis]" } } }, "localname": "ComponentsOfEquityAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "stringItemType" }, "ifrs-full_ComprehensiveIncome": { "auth_ref": [ "r0", "r27", "r91", "r93", "r99", "r204" ], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners." } }, "en-us": { "role": { "label": "Comprehensive income", "totalLabel": "Total comprehensive loss for the year" } } }, "localname": "ComprehensiveIncome", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ContractLiabilities": { "auth_ref": [ "r110", "r113" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of an entity\u2019s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer." } }, "en-us": { "role": { "label": "Contract liabilities", "negatedPeriodEndLabel": "Deferred revenue at end of period", "negatedPeriodStartLabel": "Deferred revenue at beginning of period" } } }, "localname": "ContractLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureRevenueDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CounterpartiesAxis": { "auth_ref": [ "r162" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Counterparties [axis]" } } }, "localname": "CounterpartiesAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureRevenueDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_CounterpartiesMember": { "auth_ref": [ "r162" ], "lang": { "en": { "role": { "documentation": "This member stands for the parties to the transaction other than the entity. It also represents the standard value for the 'Counterparties' axis if no other member is used." } }, "en-us": { "role": { "label": "Counterparties [member]" } } }, "localname": "CounterpartiesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureRevenueDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_CreditRiskMember": { "auth_ref": [ "r176", "r177", "r178", "r213" ], "lang": { "en": { "role": { "documentation": "This member stands for the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. [Refer: Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Credit risk" } } }, "localname": "CreditRiskMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureFinancialInstrumentsRiskManagementAndCapitalManagementDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities": { "auth_ref": [ "r242" ], "calculation": { "http://www.lavatherapeutics.com/role/DisclosureWorkingCapitalAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPositions": { "order": 4.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current accrued expenses and other current liabilities. [Refer: Accruals; Other current liabilities]" } }, "en-us": { "role": { "label": "Current accrued expenses and other current liabilities", "terseLabel": "Accrued expenses and other current liabilities", "totalLabel": "Total" } } }, "localname": "CurrentAccruedExpensesAndOtherCurrentLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureWorkingCapitalAccruedExpensesAndOtherCurrentLiabilitiesDetails", "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentAssets": { "auth_ref": [ "r14", "r95", "r204" ], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPositions": { "order": 1.0, "parentTag": "ifrs-full_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]" } }, "en-us": { "role": { "label": "Current assets", "totalLabel": "Total current assets:" } } }, "localname": "CurrentAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets [abstract]", "terseLabel": "Current assets:" } } }, "localname": "CurrentAssetsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_CurrentContractLiabilities": { "auth_ref": [ "r110" ], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPositions": { "order": 3.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current contract liabilities. [Refer: Contract liabilities]" } }, "en-us": { "role": { "label": "Current contract liabilities", "terseLabel": "Deferred revenue" } } }, "localname": "CurrentContractLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentInvestments": { "auth_ref": [ "r242" ], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPositions": { "order": 6.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current investments." } }, "en-us": { "role": { "label": "Current investments", "terseLabel": "Investments" } } }, "localname": "CurrentInvestments", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentLeaseLiabilities": { "auth_ref": [ "r118" ], "calculation": { "http://www.lavatherapeutics.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesCalc2Details": { "order": 1.0, "parentTag": "ifrs-full_LeaseLiabilities", "weight": 1.0 }, "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPositions": { "order": 2.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Current lease liabilities", "terseLabel": "Current portion", "verboseLabel": "Lease liabilities" } } }, "localname": "CurrentLeaseLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails", "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentLiabilities": { "auth_ref": [ "r15", "r97", "r204" ], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPositions": { "order": 1.0, "parentTag": "ifrs-full_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.\nEffective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period." } }, "en-us": { "role": { "label": "Current liabilities", "totalLabel": "Total current liabilities" } } }, "localname": "CurrentLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities [abstract]", "terseLabel": "Current liabilities" } } }, "localname": "CurrentLiabilitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_CurrentPrepaidExpenses": { "auth_ref": [ "r239" ], "calculation": { "http://www.lavatherapeutics.com/role/DisclosureWorkingCapitalAccruedExpensesAndOtherCurrentLiabilitiesDetailss": { "order": 2.0, "parentTag": "ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised." } }, "en-us": { "role": { "label": "Current prepaid expenses", "terseLabel": "Prepaid other expenses" } } }, "localname": "CurrentPrepaidExpenses", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureWorkingCapitalPrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets": { "auth_ref": [ "r242" ], "calculation": { "http://www.lavatherapeutics.com/role/DisclosureWorkingCapitalAccruedExpensesAndOtherCurrentLiabilitiesDetailss": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPositions": { "order": 2.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current prepayments and other current assets. [Refer: Other current assets; Current prepayments]" } }, "en-us": { "role": { "label": "Current prepayments and other current assets", "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Total" } } }, "localname": "CurrentPrepaymentsAndOtherCurrentAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureWorkingCapitalPrepaidExpensesAndOtherCurrentAssetsDetails", "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentProvisionsForEmployeeBenefits": { "auth_ref": [ "r18" ], "calculation": { "http://www.lavatherapeutics.com/role/DisclosureWorkingCapitalAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": 1.0, "parentTag": "ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current provisions for employee benefits. [Refer: Provisions for employee benefits]" } }, "en-us": { "role": { "label": "Current provisions for employee benefits", "terseLabel": "Personnel-related expenses" } } }, "localname": "CurrentProvisionsForEmployeeBenefits", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureWorkingCapitalAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentValueAddedTaxReceivables": { "auth_ref": [ "r243" ], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPositions": { "order": 4.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current value added tax receivables. [Refer: Value added tax receivables]" } }, "en-us": { "role": { "label": "Current value added tax receivables", "terseLabel": "VAT receivable" } } }, "localname": "CurrentValueAddedTaxReceivables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DebtSecuritiesMember": { "auth_ref": [ "r205", "r207" ], "lang": { "en": { "role": { "documentation": "This member stands for instruments held by the entity that represent indebtedness." } }, "en-us": { "role": { "label": "Carrying value" } } }, "localname": "DebtSecuritiesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureFinancialInstrumentsRiskManagementAndCapitalManagementDetails", "http://www.lavatherapeutics.com/role/DisclosureInvestmentsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities": { "auth_ref": [ "r210" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The decrease in contract liabilities resulting from the performance obligation being satisfied. [Refer: Contract liabilities; Performance obligations [member]]" } }, "en-us": { "role": { "label": "Decrease through performance obligation being satisfied, contract liabilities", "terseLabel": "Recognized during the period" } } }, "localname": "DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureRevenueDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DeferredTaxLiabilityAsset": { "auth_ref": [ "r34" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of deferred tax liabilities or assets. [Refer: Deferred tax liabilities; Deferred tax assets]" } }, "en-us": { "role": { "label": "Tax Differences", "terseLabel": "Tax differences" } } }, "localname": "DeferredTaxLiabilityAsset", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureTaxationTaxLossesCarryForwardDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DepreciationPropertyPlantAndEquipment": { "auth_ref": [ "r40", "r44" ], "lang": { "en": { "role": { "documentation": "The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]" } }, "en-us": { "role": { "label": "Depreciation, property, plant and equipment", "terseLabel": "Charge for the year" } } }, "localname": "DepreciationPropertyPlantAndEquipment", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DepreciationRightofuseAssets": { "auth_ref": [ "r119" ], "lang": { "en": { "role": { "documentation": "The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]" } }, "en-us": { "role": { "label": "Depreciation, right-of-use assets", "negatedLabel": "Depreciation charges" } } }, "localname": "DepreciationRightofuseAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureLeasesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory": { "auth_ref": [ "r240" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment." } }, "en-us": { "role": { "label": "Description of accounting policy for employee benefits [text block]", "terseLabel": "Employee benefits" } } }, "localname": "DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory": { "auth_ref": [ "r240" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for financial instruments. [Refer: Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Description of accounting policy for financial instruments [text block]", "terseLabel": "Financial instruments" } } }, "localname": "DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": { "auth_ref": [ "r240" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for foreign currency translation." } }, "en-us": { "role": { "label": "Description of accounting policy for foreign currency translation [text block]", "terseLabel": "Foreign currency" } } }, "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory": { "auth_ref": [ "r240" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for the impairment of assets." } }, "en-us": { "role": { "label": "Description of accounting policy for impairment of assets [text block]", "terseLabel": "Impairment of long-lived assets" } } }, "localname": "DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory": { "auth_ref": [ "r240" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for income tax." } }, "en-us": { "role": { "label": "Description of accounting policy for income tax [text block]", "terseLabel": "Income taxes" } } }, "localname": "DescriptionOfAccountingPolicyForIncomeTaxExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": { "auth_ref": [ "r240" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time." } }, "en-us": { "role": { "label": "Description of accounting policy for leases [text block]", "terseLabel": "Leases" } } }, "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": { "auth_ref": [ "r240" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for property, plant and equipment. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Description of accounting policy for property, plant and equipment [text block]", "terseLabel": "Property and equipment" } } }, "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory": { "auth_ref": [ "r240" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for provisions. [Refer: Provisions]" } }, "en-us": { "role": { "label": "Description of accounting policy for provisions [text block]", "terseLabel": "Provisions" } } }, "localname": "DescriptionOfAccountingPolicyForProvisionsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory": { "auth_ref": [ "r240" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for research and development expense. [Refer: Research and development expense]" } }, "en-us": { "role": { "label": "Description of accounting policy for research and development expense [text block]", "terseLabel": "Research and development expenses" } } }, "localname": "DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory": { "auth_ref": [ "r240" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for segment reporting." } }, "en-us": { "role": { "label": "Description of accounting policy for segment reporting [text block]", "terseLabel": "Segment information" } } }, "localname": "DescriptionOfAccountingPolicyForSegmentReportingExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": { "auth_ref": [ "r240" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]" } }, "en-us": { "role": { "label": "Description of accounting policy for share-based payment transactions [text block]", "terseLabel": "Share-based awards" } } }, "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory": { "auth_ref": [ "r240" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for taxes other than income tax. [Refer: Tax expense other than income tax expense]" } }, "en-us": { "role": { "label": "Description of accounting policy for taxes other than income tax [text block]", "terseLabel": "Value added tax" } } }, "localname": "DescriptionOfAccountingPolicyForTaxesOtherThanIncomeTaxExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents": { "auth_ref": [ "r87" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy used to determine the components of cash and cash equivalents. [Refer: Cash and cash equivalents]" } }, "en-us": { "role": { "label": "Description of accounting policy for determining components of cash and cash equivalents [text block]", "terseLabel": "Cash and cash equivalents" } } }, "localname": "DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": { "auth_ref": [ "r140" ], "lang": { "en": { "role": { "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time." } }, "en-us": { "role": { "label": "Expected volatility, share options granted", "terseLabel": "Expected annual volatility" } } }, "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationFairValueMeasurementDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_DescriptionOfOptionLifeShareOptionsGranted": { "auth_ref": [ "r140" ], "lang": { "en": { "role": { "documentation": "The option life of share options granted." } }, "en-us": { "role": { "label": "Option life, share options granted", "terseLabel": "Expected life, years" } } }, "localname": "DescriptionOfOptionLifeShareOptionsGranted", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationFairValueMeasurementDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": { "auth_ref": [ "r140" ], "lang": { "en": { "role": { "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]" } }, "en-us": { "role": { "label": "Risk free interest rate, share options granted", "terseLabel": "Risk-free interest rate" } } }, "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationFairValueMeasurementDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_DilutedEarningsLossPerShare": { "auth_ref": [ "r65", "r66" ], "lang": { "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } }, "en-us": { "role": { "label": "Diluted earnings (loss) per share", "terseLabel": "Loss per share, diluted" } } }, "localname": "DilutedEarningsLossPerShare", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureEarningsPerShareEpsDetails", "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": { "auth_ref": [ "r236" ], "lang": { "en": { "role": { "documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]" } }, "en-us": { "role": { "label": "Disclosure of accounting judgements and estimates [text block]", "terseLabel": "Significant accounting judgments, estimates and assumptions" } } }, "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureSignificantAccountingJudgmentsEstimatesAndAssumptions" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfBasisOfConsolidationExplanatory": { "auth_ref": [ "r236" ], "lang": { "en": { "role": { "documentation": "The disclosure of the basis used for consolidation." } }, "en-us": { "role": { "label": "Disclosure of basis of consolidation [text block]", "terseLabel": "Basis of consolidation" } } }, "localname": "DisclosureOfBasisOfConsolidationExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": { "auth_ref": [ "r236" ], "lang": { "en": { "role": { "documentation": "The disclosure of the basis used for the preparation of the financial statements." } }, "en-us": { "role": { "label": "Disclosure of basis of preparation of financial statements [text block]", "terseLabel": "Basis of preparation" } } }, "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfBorrowingCostsExplanatory": { "auth_ref": [ "r50" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for borrowing costs." } }, "en-us": { "role": { "label": "Disclosure of borrowing costs [text block]", "terseLabel": "Interest expense, net" } } }, "localname": "DisclosureOfBorrowingCostsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureInterestExpenseNet" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfBorrowingsExplanatory": { "auth_ref": [ "r236" ], "lang": { "en": { "role": { "documentation": "The disclosure of borrowings. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Disclosure of borrowings [text block]", "terseLabel": "Borrowings" } } }, "localname": "DisclosureOfBorrowingsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureBorrowings" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory": { "auth_ref": [ "r236" ], "lang": { "en": { "role": { "documentation": "The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]" } }, "en-us": { "role": { "label": "Disclosure of cash and cash equivalents [text block]", "terseLabel": "Cash and cash equivalents" } } }, "localname": "DisclosureOfCashAndCashEquivalentsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureCashAndCashEquivalents" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfCashFlowStatementExplanatory": { "auth_ref": [ "r89" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for a statement of cash flows." } }, "en-us": { "role": { "label": "Disclosure of cash flow statement [text block]", "terseLabel": "Cash flow statement" } } }, "localname": "DisclosureOfCashFlowStatementExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfClassesOfShareCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share capital, share premium and other capital reserves" } } }, "localname": "DisclosureOfClassesOfShareCapitalAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": { "auth_ref": [ "r24" ], "lang": { "en": { "role": { "documentation": "The disclosure of classes of share capital. [Refer: Share capital [member]]" } }, "en-us": { "role": { "label": "Disclosure of classes of share capital [text block]", "terseLabel": "Schedule of share capital" } } }, "localname": "DisclosureOfClassesOfShareCapitalExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of classes of share capital [line items]", "terseLabel": "Share capital, share premium and other capital reserves" } } }, "localname": "DisclosureOfClassesOfShareCapitalLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesCommonSharesDetails", "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesMajorShareholdersDetails", "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesPreferenceShareDetails", "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesSummaryDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfClassesOfShareCapitalTable": { "auth_ref": [ "r24" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to classes of share capital." } }, "en-us": { "role": { "label": "Disclosure of classes of share capital [table]" } } }, "localname": "DisclosureOfClassesOfShareCapitalTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesCommonSharesDetails", "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesMajorShareholdersDetails", "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesPreferenceShareDetails", "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesSummaryDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfContingentLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies" } } }, "localname": "DisclosureOfContingentLiabilitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfContingentLiabilitiesExplanatory": { "auth_ref": [ "r71" ], "lang": { "en": { "role": { "documentation": "The disclosure of contingent liabilities. [Refer: Contingent liabilities [member]]" } }, "en-us": { "role": { "label": "Disclosure of contingent liabilities [text block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "DisclosureOfContingentLiabilitiesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfContingentLiabilitiesLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of contingent liabilities [line items]" } } }, "localname": "DisclosureOfContingentLiabilitiesLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfContingentLiabilitiesTable": { "auth_ref": [ "r71" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to contingent liabilities." } }, "en-us": { "role": { "label": "Disclosure of contingent liabilities [table]" } } }, "localname": "DisclosureOfContingentLiabilitiesTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Borrowings." } } }, "localname": "DisclosureOfDetailedInformationAboutBorrowingsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of detailed information about borrowings [line items]" } } }, "localname": "DisclosureOfDetailedInformationAboutBorrowingsLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureBorrowingsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable": { "auth_ref": [ "r253" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to details of borrowings." } }, "en-us": { "role": { "label": "Disclosure of detailed information about borrowings [table]" } } }, "localname": "DisclosureOfDetailedInformationAboutBorrowingsTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureBorrowingsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory": { "auth_ref": [ "r148", "r153", "r158" ], "lang": { "en": { "role": { "documentation": "The disclosure of detailed information about financial instruments. [Refer: Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Disclosure of detailed information about financial instruments [text block]", "terseLabel": "Schedule of financial assets and financial liabilities" } } }, "localname": "DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureFinancialInstrumentsRiskManagementAndCapitalManagementTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": { "auth_ref": [ "r43" ], "lang": { "en": { "role": { "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [text block]", "terseLabel": "Schedule of movements in property and equipment" } } }, "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosurePropertyAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue" } } }, "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of disaggregation of revenue from contracts with customers [line items]", "terseLabel": "Revenue" } } }, "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureRevenueDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable": { "auth_ref": [ "r112" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to the disaggregation of revenue from contracts with customers." } }, "en-us": { "role": { "label": "Disclosure of disaggregation of revenue from contracts with customers [table]" } } }, "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureRevenueDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfEarningsPerShareExplanatory": { "auth_ref": [ "r68" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for earnings per share." } }, "en-us": { "role": { "label": "Disclosure of earnings per share [text block]", "terseLabel": "Earnings per share (EPS)" } } }, "localname": "DisclosureOfEarningsPerShareExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureEarningsPerShareEps" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory": { "auth_ref": [ "r49" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for the effect of changes in foreign exchange rates." } }, "en-us": { "role": { "label": "Disclosure of effect of changes in foreign exchange rates [text block]", "terseLabel": "Foreign currency exchange loss, net" } } }, "localname": "DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureForeignCurrencyExchangeLossNet" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of fair value measurement of assets [line items]" } } }, "localname": "DisclosureOfFairValueMeasurementOfAssetsLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureInvestmentsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable": { "auth_ref": [ "r108" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to the fair value measurement of assets." } }, "en-us": { "role": { "label": "Disclosure of fair value measurement of assets [table]" } } }, "localname": "DisclosureOfFairValueMeasurementOfAssetsTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureInvestmentsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfFinancialAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments" } } }, "localname": "DisclosureOfFinancialAssetsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfFinancialAssetsExplanatory": { "auth_ref": [ "r158" ], "lang": { "en": { "role": { "documentation": "The disclosure of financial assets. [Refer: Financial assets]" } }, "en-us": { "role": { "label": "Disclosure of financial assets [text block]", "terseLabel": "Investments in Debt Securities" } } }, "localname": "DisclosureOfFinancialAssetsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureInvestments" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financial instruments, risk management and capital management" } } }, "localname": "DisclosureOfFinancialInstrumentsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": { "auth_ref": [ "r163" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for financial instruments." } }, "en-us": { "role": { "label": "Disclosure of financial instruments [text block]", "terseLabel": "Financial instruments, risk management and capital management" } } }, "localname": "DisclosureOfFinancialInstrumentsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureFinancialInstrumentsRiskManagementAndCapitalManagement" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of detailed information about financial instruments [line items]", "terseLabel": "Financial instruments, risk management and capital management" } } }, "localname": "DisclosureOfFinancialInstrumentsLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureFinancialInstrumentsRiskManagementAndCapitalManagementDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfFinancialInstrumentsTable": { "auth_ref": [ "r148", "r153", "r158" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to details of financial instruments." } }, "en-us": { "role": { "label": "Disclosure of detailed information about financial instruments [table]" } } }, "localname": "DisclosureOfFinancialInstrumentsTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureFinancialInstrumentsRiskManagementAndCapitalManagementDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory": { "auth_ref": [ "r236" ], "lang": { "en": { "role": { "documentation": "The disclosure of general and administrative expenses. [Refer: Administrative expenses]" } }, "en-us": { "role": { "label": "Disclosure of general and administrative expense [text block]", "terseLabel": "General and administrative expenses" } } }, "localname": "DisclosureOfGeneralAndAdministrativeExpenseExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureGeneralAndAdministrativeExpenses" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory": { "auth_ref": [ "r6" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for general information about financial statements." } }, "en-us": { "role": { "label": "Disclosure of general information about financial statements [text block]", "terseLabel": "Corporate and Company information" } } }, "localname": "DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureCorporateAndCompanyInformation" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfIncomeTaxExplanatory": { "auth_ref": [ "r36" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for income taxes." } }, "en-us": { "role": { "label": "Disclosure of income tax [text block]", "terseLabel": "Taxation" } } }, "localname": "DisclosureOfIncomeTaxExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureTaxation" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory": { "auth_ref": [ "r141" ], "lang": { "en": { "role": { "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options." } }, "en-us": { "role": { "label": "Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]", "terseLabel": "Schedule of assumptions used in the measurement of the fair values and the weighted average fair value of the share options granted" } } }, "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfInformationAboutConsolidatedStructuredEntitiesExplanatory": { "auth_ref": [ "r104" ], "lang": { "en": { "role": { "documentation": "The disclosure of information about consolidated structured entities. [Refer: Consolidated structured entities [member]]" } }, "en-us": { "role": { "label": "Disclosure of information about consolidated structured entities [text block]", "terseLabel": "Schedule of percentage of equity interest in subsidiary" } } }, "localname": "DisclosureOfInformationAboutConsolidatedStructuredEntitiesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureCorporateAndCompanyInformationTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory": { "auth_ref": [ "r236" ], "lang": { "en": { "role": { "documentation": "The disclosure of information about key management personnel. [Refer: Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Disclosure of information about key management personnel [text block]", "terseLabel": "Schedule of key management compensation" } } }, "localname": "DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureRelatedPartiesTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfLeasesExplanatory": { "auth_ref": [ "r128", "r129" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for leases." } }, "en-us": { "role": { "label": "Disclosure of leases [text block]", "terseLabel": "Leases" } } }, "localname": "DisclosureOfLeasesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureLeases" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory": { "auth_ref": [ "r136" ], "lang": { "en": { "role": { "documentation": "The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Disclosure of number and weighted average exercise prices of share options [text block]", "terseLabel": "Schedule of information about share-based awards" } } }, "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory": { "auth_ref": [ "r236" ], "lang": { "en": { "role": { "documentation": "The disclosure of prepayments and other assets. [Refer: Other assets; Prepayments]" } }, "en-us": { "role": { "label": "Disclosure of prepayments and other assets [text block]", "terseLabel": "Schedule of prepaid expenses and other current assets" } } }, "localname": "DisclosureOfPrepaymentsAndOtherAssetsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureWorkingCapitalTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property and equipment" } } }, "localname": "DisclosureOfPropertyPlantAndEquipmentAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": { "auth_ref": [ "r46" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for property, plant and equipment." } }, "en-us": { "role": { "label": "Disclosure of property, plant and equipment [text block]", "terseLabel": "Property and equipment" } } }, "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosurePropertyAndEquipment" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [line items]", "terseLabel": "Property, plant, and equipment" } } }, "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosurePropertyAndEquipmentDetails", "http://www.lavatherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r43" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to details of property, plant and equipment." } }, "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [table]" } } }, "localname": "DisclosureOfPropertyPlantAndEquipmentTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosurePropertyAndEquipmentDetails", "http://www.lavatherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory": { "auth_ref": [ "r124" ], "lang": { "en": { "role": { "documentation": "The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]" } }, "en-us": { "role": { "label": "Disclosure of quantitative information about right-of-use assets [text block]", "terseLabel": "Schedule of right-of-use assets" } } }, "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of quantitative information about right-of-use assets [line items]" } } }, "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable": { "auth_ref": [ "r124" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to right-of-use assets." } }, "en-us": { "role": { "label": "Disclosure of quantitative information about right-of-use assets [table]" } } }, "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfRelatedPartyExplanatory": { "auth_ref": [ "r59" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for related parties." } }, "en-us": { "role": { "label": "Disclosure of related party [text block]", "terseLabel": "Related parties" } } }, "localname": "DisclosureOfRelatedPartyExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureRelatedParties" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory": { "auth_ref": [ "r236" ], "lang": { "en": { "role": { "documentation": "The disclosure of research and development expense. [Refer: Research and development expense]" } }, "en-us": { "role": { "label": "Disclosure of research and development expense [text block]", "terseLabel": "Research and development expenses" } } }, "localname": "DisclosureOfResearchAndDevelopmentExpenseExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureResearchAndDevelopmentExpenses" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory": { "auth_ref": [ "r116", "r117" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for revenue from contracts with customers." } }, "en-us": { "role": { "label": "Disclosure of revenue from contracts with customers [text block]", "terseLabel": "Revenue" } } }, "localname": "DisclosureOfRevenueFromContractsWithCustomersExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureRevenue" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": { "auth_ref": [ "r25" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for share capital, reserves and other equity interest." } }, "en-us": { "role": { "label": "Disclosure of share capital, reserves and other equity interest [text block]", "terseLabel": "Share capital, share premium and other capital reserves" } } }, "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReserves" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": { "auth_ref": [ "r130" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for share-based payment arrangements." } }, "en-us": { "role": { "label": "Disclosure of share-based payment arrangements [text block]", "terseLabel": "Share-based compensation" } } }, "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensation" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of subsidiaries [line items]" } } }, "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureCorporateAndCompanyInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable": { "auth_ref": [ "r62", "r64", "r103" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to subsidiaries." } }, "en-us": { "role": { "label": "Disclosure of subsidiaries [table]" } } }, "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureCorporateAndCompanyInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory": { "auth_ref": [ "r4" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for significant accounting policies applied by the entity." } }, "en-us": { "role": { "label": "Disclosure of significant accounting policies [text block]", "terseLabel": "Summary of significant accounting policies" } } }, "localname": "DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]", "terseLabel": "Taxation" } } }, "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureTaxationDetails", "http://www.lavatherapeutics.com/role/DisclosureTaxationTaxLossesCarryForwardDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable": { "auth_ref": [ "r35" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to temporary differences, unused tax losses and unused tax credits." } }, "en-us": { "role": { "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]" } } }, "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureTaxationDetails", "http://www.lavatherapeutics.com/role/DisclosureTaxationTaxLossesCarryForwardDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based compensation" } } }, "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]", "terseLabel": "Share-based compensation" } } }, "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationFairValueMeasurementDetails", "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationNarrativesDetails", "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationNumberOfOptionAndExercisePriceDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": { "auth_ref": [ "r139" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements." } }, "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [table]" } } }, "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationFairValueMeasurementDetails", "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationNarrativesDetails", "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationNumberOfOptionAndExercisePriceDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": { "auth_ref": [ "r236" ], "lang": { "en": { "role": { "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]" } }, "en-us": { "role": { "label": "Disclosure of trade and other payables [text block]", "terseLabel": "Trade payables and other" } } }, "localname": "DisclosureOfTradeAndOtherPayablesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureTradePayablesAndOther" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related parties" } } }, "localname": "DisclosureOfTransactionsBetweenRelatedPartiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory": { "auth_ref": [ "r56" ], "lang": { "en": { "role": { "documentation": "The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]]" } }, "en-us": { "role": { "label": "Disclosure of transactions between related parties [text block]", "terseLabel": "Schedule of director and shareholder compensation" } } }, "localname": "DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureRelatedPartiesTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of transactions between related parties [line items]" } } }, "localname": "DisclosureOfTransactionsBetweenRelatedPartiesLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureRelatedPartiesDirectorAndShareholderCompensationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": { "auth_ref": [ "r57" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to transactions between related parties." } }, "en-us": { "role": { "label": "Disclosure of transactions between related parties [table]" } } }, "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureRelatedPartiesDirectorAndShareholderCompensationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings per share (EPS)", "terseLabel": "Loss per share" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "xbrltype": "stringItemType" }, "ifrs-full_EarningsPerShareExplanatory": { "auth_ref": [ "r65" ], "lang": { "en": { "role": { "documentation": "The disclosure of earnings per share." } }, "en-us": { "role": { "label": "Earnings per share [text block]", "terseLabel": "Schedule of loss and share data used in the basic and diluted EPS calculations" } } }, "localname": "EarningsPerShareExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureEarningsPerShareEpsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": { "auth_ref": [ "r83", "r84" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]" } }, "en-us": { "role": { "label": "Effect of exchange rate changes on cash and cash equivalents", "terseLabel": "Effects of exchange rate changes on the balance of cash held in foreign currencies" } } }, "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EntitysTotalForSubsidiariesMember": { "auth_ref": [ "r62", "r64", "r103" ], "lang": { "en": { "role": { "documentation": "This member stands for the standard value for the 'Subsidiaries' axis if no other member is used." } }, "en-us": { "role": { "label": "Entity's total for subsidiaries [member]" } } }, "localname": "EntitysTotalForSubsidiariesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureCorporateAndCompanyInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_Equity": { "auth_ref": [ "r11", "r19", "r90", "r92", "r105", "r106", "r107" ], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPositions": { "order": 1.0, "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities." } }, "en-us": { "role": { "label": "Equity", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning Balance", "totalLabel": "Total equity" } } }, "localname": "Equity", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity", "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [abstract]", "terseLabel": "Equity" } } }, "localname": "EquityAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_EquityAndLiabilities": { "auth_ref": [ "r11" ], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPositions": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]" } }, "en-us": { "role": { "label": "Equity and liabilities", "totalLabel": "Total equity and liabilities" } } }, "localname": "EquityAndLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EquityAndLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity and liabilities [abstract]", "terseLabel": "Equity and Liabilities" } } }, "localname": "EquityAndLiabilitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_EquityMember": { "auth_ref": [ "r3" ], "lang": { "en": { "role": { "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used." } }, "en-us": { "role": { "label": "Equity [member]" } } }, "localname": "EquityMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_ExercisePriceShareOptionsGranted2019": { "auth_ref": [ "r140" ], "lang": { "en": { "role": { "documentation": "The exercise price of share options granted." } }, "en-us": { "role": { "label": "Exercise price, share options granted", "terseLabel": "Exercise price" } } }, "localname": "ExercisePriceShareOptionsGranted2019", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationFairValueMeasurementDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": { "auth_ref": [ "r142" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets." } }, "en-us": { "role": { "label": "Expense from share-based payment transactions", "terseLabel": "Share-based compensation expenses" } } }, "localname": "ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationNarrativesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory": { "auth_ref": [ "r114" ], "lang": { "en": { "role": { "documentation": "The explanation of the significant changes in the contract assets and the contract liabilities. [Refer: Contract assets; Contract liabilities]" } }, "en-us": { "role": { "label": "Explanation of significant changes in contract assets and contract liabilities [text block]", "terseLabel": "Schedule of changes in deferred revenue" } } }, "localname": "ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureRevenueTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_FinancialAssets": { "auth_ref": [ "r147", "r151", "r152", "r154", "r214" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose the entity\u2019s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]" } }, "en-us": { "role": { "label": "Financial assets", "terseLabel": "Financial assets" } } }, "localname": "FinancialAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureFinancialInstrumentsRiskManagementAndCapitalManagementDetails", "http://www.lavatherapeutics.com/role/DisclosureInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember": { "auth_ref": [ "r159" ], "lang": { "en": { "role": { "documentation": "This member stands for the financial assets at amortised cost category. [Refer: Financial assets at amortised cost]" } }, "en-us": { "role": { "label": "Financial assets measured at amortized cost" } } }, "localname": "FinancialAssetsAtAmortisedCostCategoryMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureFinancialInstrumentsRiskManagementAndCapitalManagementDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_FinancialAssetsCategoryMember": { "auth_ref": [ "r161" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated categories of financial assets. It also represents the standard value for the 'Categories of financial assets' axis if no other member is used. [Refer: Financial assets]" } }, "en-us": { "role": { "label": "Financial assets, category [member]" } } }, "localname": "FinancialAssetsCategoryMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureFinancialInstrumentsRiskManagementAndCapitalManagementDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_FinancialAssetsMember": { "auth_ref": [ "r156", "r157", "r172", "r182", "r183", "r184" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated classes of financial assets. It also represents the standard value for the 'Classes of financial assets' axis if no other member is used. [Refer: Financial assets]" } }, "en-us": { "role": { "label": "Financial assets, class [member]" } } }, "localname": "FinancialAssetsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureFinancialInstrumentsRiskManagementAndCapitalManagementDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_FinancialLiabilities": { "auth_ref": [ "r147" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]" } }, "en-us": { "role": { "label": "Financial liabilities", "terseLabel": "Financial liabilities" } } }, "localname": "FinancialLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureFinancialInstrumentsRiskManagementAndCapitalManagementDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember": { "auth_ref": [ "r160", "r185" ], "lang": { "en": { "role": { "documentation": "This member stands for the financial liabilities at amortised cost category. [Refer: Financial liabilities at amortised cost]" } }, "en-us": { "role": { "label": "Financial liabilities measured at amortized cost" } } }, "localname": "FinancialLiabilitiesAtAmortisedCostCategoryMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureFinancialInstrumentsRiskManagementAndCapitalManagementDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_FinancialLiabilitiesCategoryMember": { "auth_ref": [ "r161" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated categories of financial liabilities. It also represents the standard value for the 'Categories of financial liabilities' axis if no other member is used. [Refer: Financial assets]" } }, "en-us": { "role": { "label": "Financial liabilities, category [member]" } } }, "localname": "FinancialLiabilitiesCategoryMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureFinancialInstrumentsRiskManagementAndCapitalManagementDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_FinancialLiabilitiesMember": { "auth_ref": [ "r156", "r157", "r172", "r183" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated classes financial liabilities. It also represents the standard value for the 'Classes of financial liabilities' axis if no other member is used. [Refer: Financial liabilities]" } }, "en-us": { "role": { "label": "Financial liabilities, class [member]" } } }, "localname": "FinancialLiabilitiesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureFinancialInstrumentsRiskManagementAndCapitalManagementDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ForeignExchangeRatesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Foreign currency exchange loss, net" } } }, "localname": "ForeignExchangeRatesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss": { "auth_ref": [ "r5", "r47" ], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "lvtx_NonoperatingExpenses", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Foreign exchange gain (loss)", "verboseLabel": "Foreign currency exchange loss, net" } } }, "localname": "GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GeneralAndAdministrativeExpense": { "auth_ref": [ "r239" ], "calculation": { "http://www.lavatherapeutics.com/role/DisclosureGeneralAndAdministrativeExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense relating to general and administrative activities of the entity." } }, "en-us": { "role": { "label": "General and administrative expense", "negatedLabel": "General and administrative", "totalLabel": "Total general and administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureGeneralAndAdministrativeExpensesDetails", "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GeographicalAreasAxis": { "auth_ref": [ "r171", "r192", "r211", "r221" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Geographical areas [axis]" } } }, "localname": "GeographicalAreasAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationFairValueMeasurementDetails", "http://www.lavatherapeutics.com/role/DisclosureTaxationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_GeographicalAreasMember": { "auth_ref": [ "r171", "r192", "r211", "r221" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used." } }, "en-us": { "role": { "label": "Geographical areas [member]" } } }, "localname": "GeographicalAreasMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationFairValueMeasurementDetails", "http://www.lavatherapeutics.com/role/DisclosureTaxationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_GovernmentGrants": { "auth_ref": [ "r242" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of assistance by government in the form of transfers of resources to an entity in return for past or future compliance with certain conditions relating to the operating activities of the entity, recognised as deferred income. They exclude those forms of government assistance that cannot reasonably have a value placed upon them and transactions with government that cannot be distinguished from the normal trading transactions of the entity. [Refer: Deferred income other than contract liabilities; Government [member]]" } }, "en-us": { "role": { "label": "Government grants", "terseLabel": "Government grants" } } }, "localname": "GovernmentGrants", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureResearchAndDevelopmentExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GrossCarryingAmountMember": { "auth_ref": [ "r38", "r72", "r77", "r80", "r143", "r152", "r154", "r214", "r255", "r256" ], "lang": { "en": { "role": { "documentation": "This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon. [Refer: Depreciation and amortisation expense; Impairment loss]" } }, "en-us": { "role": { "label": "Gross carrying amount [member]" } } }, "localname": "GrossCarryingAmountMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_IncomeTaxExpenseContinuingOperations": { "auth_ref": [ "r28", "r30", "r31", "r32", "r60", "r102", "r165" ], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]" } }, "en-us": { "role": { "label": "Tax expense (income)", "negatedLabel": "Income tax expense" } } }, "localname": "IncomeTaxExpenseContinuingOperations", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureTaxationDetails", "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges": { "auth_ref": [ "r86" ], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } }, "en-us": { "role": { "label": "Increase (decrease) in cash and cash equivalents before effect of exchange rate changes", "totalLabel": "Net increase (decrease) in cash and cash equivalents" } } }, "localname": "IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments": { "auth_ref": [ "r237" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the conversion of convertible instruments." } }, "en-us": { "role": { "label": "Increase (decrease) through conversion of convertible instruments, equity", "terseLabel": "Conversion of preference shares" } } }, "localname": "IncreaseDecreaseThroughConversionOfConvertibleInstruments", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughCumulativeCatchupAdjustmentsToRevenueContractLiabilities": { "auth_ref": [ "r209" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in contract liabilities resulting from cumulative catch-up adjustments to revenue. [Refer: Contract liabilities; Revenue from contracts with customers]" } }, "en-us": { "role": { "label": "Increase (decrease) through cumulative catch-up adjustments to revenue, contract liabilities", "negatedLabel": "Deferral of revenue" } } }, "localname": "IncreaseDecreaseThroughCumulativeCatchupAdjustmentsToRevenueContractLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureRevenueDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment": { "auth_ref": [ "r41" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in property, plant and equipment resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Increase (decrease) through net exchange differences, property, plant and equipment", "terseLabel": "Foreign currency translation adjustment" } } }, "localname": "IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": { "auth_ref": [ "r2" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]" } }, "en-us": { "role": { "label": "Increase (decrease) through share-based payment transactions, equity", "terseLabel": "Share-based compensation expense" } } }, "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InterestCostsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Interest expense, net" } } }, "localname": "InterestCostsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_InterestExpense": { "auth_ref": [ "r101", "r164", "r170" ], "calculation": { "http://www.lavatherapeutics.com/role/DisclosureInterestExpenseNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense arising from interest." } }, "en-us": { "role": { "label": "Interest expense", "totalLabel": "Interest expense, net" } } }, "localname": "InterestExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureInterestExpenseNetDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InterestExpenseOnBorrowings": { "auth_ref": [ "r239" ], "calculation": { "http://www.lavatherapeutics.com/role/DisclosureInterestExpenseNetDetails": { "order": 1.0, "parentTag": "ifrs-full_InterestExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of interest expense on borrowings. [Refer: Interest expense; Borrowings]" } }, "en-us": { "role": { "label": "Interest expense on borrowings", "terseLabel": "Interest expense on borrowings and deposits, net" } } }, "localname": "InterestExpenseOnBorrowings", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureBorrowingsDetails", "http://www.lavatherapeutics.com/role/DisclosureInterestExpenseNetDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InterestExpenseOnLeaseLiabilities": { "auth_ref": [ "r120" ], "calculation": { "http://www.lavatherapeutics.com/role/DisclosureInterestExpenseNetDetails": { "order": 2.0, "parentTag": "ifrs-full_InterestExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of interest expense on lease liabilities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Interest expense on lease liabilities", "terseLabel": "Interest expense related to leases" } } }, "localname": "InterestExpenseOnLeaseLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureInterestExpenseNetDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InterestRevenueExpense": { "auth_ref": [ "r166", "r170", "r245" ], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "lvtx_NonoperatingExpenses", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income or expense arising from interest. [Refer: Interest expense; Interest income]" } }, "en-us": { "role": { "label": "Interest income (expense)", "terseLabel": "Interest expense, net" } } }, "localname": "InterestRevenueExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IssueOfEquity": { "auth_ref": [ "r2" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase in equity through the issue of equity instruments." } }, "en-us": { "role": { "label": "Issue of equity", "terseLabel": "Issuance of stock" } } }, "localname": "IssueOfEquity", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IssuedCapital": { "auth_ref": [ "r189" ], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPositions": { "order": 1.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The nominal value of capital issued." } }, "en-us": { "role": { "label": "Issued capital", "terseLabel": "Share capital" } } }, "localname": "IssuedCapital", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IssuedCapitalMember": { "auth_ref": [ "r3" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing issued capital." } }, "en-us": { "role": { "label": "Share capital" } } }, "localname": "IssuedCapitalMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_KeyManagementPersonnelCompensation": { "auth_ref": [ "r54" ], "calculation": { "http://www.lavatherapeutics.com/role/DisclosureRelatedPartiesKeyManagementCompensationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Key management personnel compensation", "totalLabel": "Total key management compensation" } } }, "localname": "KeyManagementPersonnelCompensation", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureRelatedPartiesKeyManagementCompensationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits": { "auth_ref": [ "r52" ], "calculation": { "http://www.lavatherapeutics.com/role/DisclosureRelatedPartiesKeyManagementCompensationDetails": { "order": 3.0, "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of post-employment benefits. [Refer: Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Key management personnel compensation, post-employment benefits", "terseLabel": "Post-employment benefits" } } }, "localname": "KeyManagementPersonnelCompensationPostemploymentBenefits", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureRelatedPartiesKeyManagementCompensationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": { "auth_ref": [ "r53" ], "calculation": { "http://www.lavatherapeutics.com/role/DisclosureRelatedPartiesKeyManagementCompensationDetails": { "order": 2.0, "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Key management personnel compensation, share-based payment", "terseLabel": "Share-based payments" } } }, "localname": "KeyManagementPersonnelCompensationSharebasedPayment", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureRelatedPartiesKeyManagementCompensationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": { "auth_ref": [ "r51" ], "calculation": { "http://www.lavatherapeutics.com/role/DisclosureRelatedPartiesKeyManagementCompensationDetails": { "order": 1.0, "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Key management personnel compensation, short-term employee benefits", "terseLabel": "Short term employee benefits" } } }, "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureRelatedPartiesKeyManagementCompensationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember": { "auth_ref": [ "r125", "r126", "r181", "r215", "r217", "r239" ], "lang": { "en": { "role": { "documentation": "This member stands for a time band of later than one year and not later than two years." } }, "en-us": { "role": { "label": "2023" } } }, "localname": "LaterThanOneYearAndNotLaterThanTwoYearsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember": { "auth_ref": [ "r125", "r126", "r181", "r215", "r217", "r239" ], "lang": { "en": { "role": { "documentation": "This member stands for a time band of later than three years and not later than four years." } }, "en-us": { "role": { "label": "2025" } } }, "localname": "LaterThanThreeYearsAndNotLaterThanFourYearsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember": { "auth_ref": [ "r125", "r126", "r181", "r215", "r217", "r239" ], "lang": { "en": { "role": { "documentation": "This member stands for a time band of later than two years and not later than three years." } }, "en-us": { "role": { "label": "2024" } } }, "localname": "LaterThanTwoYearsAndNotLaterThanThreeYearsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LeaseLiabilities": { "auth_ref": [ "r118" ], "calculation": { "http://www.lavatherapeutics.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesCalc2Details": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.lavatherapeutics.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "lvtx_UndiscountedLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration." } }, "en-us": { "role": { "label": "Lease liabilities.", "totalLabel": "Total lease liabilities" } } }, "localname": "LeaseLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_LeaseLiabilitiesMember": { "auth_ref": [ "r201", "r203" ], "lang": { "en": { "role": { "documentation": "This member stands for lease liabilities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Lease liabilities" } } }, "localname": "LeaseLiabilitiesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureFinancialInstrumentsRiskManagementAndCapitalManagementDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_Liabilities": { "auth_ref": [ "r11", "r105", "r106", "r107", "r166", "r169" ], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPositions": { "order": 2.0, "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } }, "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_LongtermBorrowings": { "auth_ref": [ "r242" ], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPositions": { "order": 3.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The non-current portion of non-current borrowings. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Non-current portion of non-current borrowings", "terseLabel": "Long-term borrowings", "verboseLabel": "Borrowings" } } }, "localname": "LongtermBorrowings", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureBorrowingsDetails", "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_MarketRiskMember": { "auth_ref": [ "r176", "r177", "r178", "r179", "r213" ], "lang": { "en": { "role": { "documentation": "This member stands for the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk comprises three types of risk: currency risk, interest rate risk and other price risk. [Refer: Currency risk [member]; Interest rate risk [member]; Other price risk [member]; Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Market risk" } } }, "localname": "MarketRiskMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureFinancialInstrumentsRiskManagementAndCapitalManagementDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_MaturityAxis": { "auth_ref": [ "r13", "r115", "r125", "r126", "r146", "r155", "r173", "r174", "r175", "r181", "r193", "r215" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Maturity [axis]" } } }, "localname": "MaturityAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_MeasurementAxis": { "auth_ref": [ "r75", "r79", "r105" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Measurement [axis]" } } }, "localname": "MeasurementAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureInvestmentsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_NetForeignExchangeLoss": { "auth_ref": [ "r241", "r247" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The net loss arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]" } }, "en-us": { "role": { "label": "Net foreign exchange loss", "terseLabel": "Foreign currency exchange loss, net" } } }, "localname": "NetForeignExchangeLoss", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureForeignCurrencyExchangeLossNetDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentAssets": { "auth_ref": [ "r14", "r96", "r204" ], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPositions": { "order": 2.0, "parentTag": "ifrs-full_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]" } }, "en-us": { "role": { "label": "Non-current assets", "totalLabel": "Total non-current assets" } } }, "localname": "NoncurrentAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-current assets [abstract]", "terseLabel": "Non-current assets:" } } }, "localname": "NoncurrentAssetsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_NoncurrentContractLiabilities": { "auth_ref": [ "r110" ], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPositions": { "order": 1.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of non-current contract liabilities. [Refer: Contract liabilities]" } }, "en-us": { "role": { "label": "Non-current contract liabilities", "terseLabel": "Deferred revenue" } } }, "localname": "NoncurrentContractLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentLeaseLiabilities": { "auth_ref": [ "r118" ], "calculation": { "http://www.lavatherapeutics.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesCalc2Details": { "order": 2.0, "parentTag": "ifrs-full_LeaseLiabilities", "weight": 1.0 }, "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPositions": { "order": 2.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Non-current lease liabilities", "terseLabel": "Non-current portion", "verboseLabel": "Lease liabilities" } } }, "localname": "NoncurrentLeaseLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails", "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentLiabilities": { "auth_ref": [ "r15", "r98", "r204" ], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPositions": { "order": 2.0, "parentTag": "ifrs-full_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]" } }, "en-us": { "role": { "label": "Non-current liabilities", "totalLabel": "Total non-current liabilities" } } }, "localname": "NoncurrentLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-current liabilities [abstract]", "terseLabel": "Non-current liabilities" } } }, "localname": "NoncurrentLiabilitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_NotLaterThanOneYearMember": { "auth_ref": [ "r12", "r125", "r126", "r181", "r215", "r217" ], "lang": { "en": { "role": { "documentation": "This member stands for a time band of not later than one year." } }, "en-us": { "role": { "label": "2022" } } }, "localname": "NotLaterThanOneYearMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_NotionalAmount": { "auth_ref": [ "r239" ], "lang": { "en": { "role": { "documentation": "The nominal or face amount of a financial instrument, used to calculate payments made on that instrument." } }, "en-us": { "role": { "label": "Notional amount", "terseLabel": "Innovation Credit received" } } }, "localname": "NotionalAmount", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NumberOfOutstandingShareOptions": { "auth_ref": [ "r131", "r134", "r138" ], "lang": { "en": { "role": { "documentation": "The number of share options outstanding in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of share options outstanding in share-based payment arrangement", "periodEndLabel": "Outstanding at ending, Number of options", "periodStartLabel": "Outstanding at Beginning, Number of options" } } }, "localname": "NumberOfOutstandingShareOptions", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationNumberOfOptionAndExercisePriceDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement": { "auth_ref": [ "r135" ], "lang": { "en": { "role": { "documentation": "The number of share options exercisable in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of share options exercisable in share-based payment arrangement", "terseLabel": "Exercisable, Number of options" } } }, "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentArrangement", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationNumberOfOptionAndExercisePriceDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": { "auth_ref": [ "r132" ], "lang": { "en": { "role": { "documentation": "The number of share options granted in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of share options granted in share-based payment arrangement", "terseLabel": "Granted, Number of options", "verboseLabel": "Number of shares granted" } } }, "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationNarrativesDetails", "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationNumberOfOptionAndExercisePriceDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfSharesAuthorised": { "auth_ref": [ "r20" ], "lang": { "en": { "role": { "documentation": "The number of shares authorised." } }, "en-us": { "role": { "label": "Number of shares authorised", "terseLabel": "Authorized" } } }, "localname": "NumberOfSharesAuthorised", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesSummaryDetails" ], "xbrltype": "sharesItemType" }, "ifrs-full_NumberOfSharesIssuedAndFullyPaid": { "auth_ref": [ "r21" ], "lang": { "en": { "role": { "documentation": "The number of shares issued by the entity, for which full payment has been received." } }, "en-us": { "role": { "label": "Number of shares issued and fully paid", "terseLabel": "Issued and fully paid" } } }, "localname": "NumberOfSharesIssuedAndFullyPaid", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesSummaryDetails" ], "xbrltype": "sharesItemType" }, "ifrs-full_NumberOfSharesOutstanding": { "auth_ref": [ "r23" ], "lang": { "en": { "role": { "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]" } }, "en-us": { "role": { "label": "Number of shares outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning Balance (in shares)" } } }, "localname": "NumberOfSharesOutstanding", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "sharesItemType" }, "ifrs-full_OfficeEquipmentMember": { "auth_ref": [ "r191" ], "lang": { "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing equipment used to support office functions, not specifically used in the production process. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Office equipment" } } }, "localname": "OfficeEquipmentMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosurePropertyAndEquipmentDetails", "http://www.lavatherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_OperatingExpense": { "auth_ref": [ "r245" ], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of all operating expenses." } }, "en-us": { "role": { "label": "Operating expense", "negatedTotalLabel": "Total operating expenses" } } }, "localname": "OperatingExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OrdinarySharesMember": { "auth_ref": [ "r65", "r244" ], "lang": { "en": { "role": { "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments. It also represents the standard value for the 'Classes of ordinary shares' axis if no other member is used." } }, "en-us": { "role": { "label": "Common share" } } }, "localname": "OrdinarySharesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesCommonSharesDetails", "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesPreferenceShareDetails", "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesSummaryDetails", "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_OtherComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other comprehensive income [abstract]", "terseLabel": "Other comprehensive loss" } } }, "localname": "OtherComprehensiveIncomeAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "xbrltype": "stringItemType" }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": { "auth_ref": [ "r16", "r29" ], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations", "terseLabel": "Foreign currency translation adjustment for the year" } } }, "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherShorttermProvisions": { "auth_ref": [ "r18" ], "calculation": { "http://www.lavatherapeutics.com/role/DisclosureWorkingCapitalAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": 5.0, "parentTag": "ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current provisions other than provisions for employee benefits. [Refer: Provisions]" } }, "en-us": { "role": { "label": "Other current provisions", "terseLabel": "Other" } } }, "localname": "OtherShorttermProvisions", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureWorkingCapitalAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ParValuePerShare": { "auth_ref": [ "r22" ], "lang": { "en": { "role": { "documentation": "The nominal value per share." } }, "en-us": { "role": { "label": "Par value per share", "terseLabel": "Par value" } } }, "localname": "ParValuePerShare", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesCommonSharesDetails", "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesSummaryDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": { "auth_ref": [ "r200" ], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Payments of lease liabilities, classified as financing activities", "negatedLabel": "Payment of principal portion of lease liabilities" } } }, "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PaymentsToAcquireOrRedeemEntitysShares": { "auth_ref": [ "r198" ], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow to acquire or redeem entity's shares." } }, "en-us": { "role": { "label": "Payments to acquire or redeem entity's shares", "negatedLabel": "Payment of Series A preferred and common shares repurchased" } } }, "localname": "PaymentsToAcquireOrRedeemEntitysShares", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PreferenceSharesMember": { "auth_ref": [ "r244" ], "lang": { "en": { "role": { "documentation": "This member stands for equity instruments that are senior in some aspects to ordinary shares, but subordinate to debt instruments in terms of claim. [Refer: Ordinary shares [member]]" } }, "en-us": { "role": { "label": "Preference share" } } }, "localname": "PreferenceSharesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesSummaryDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_PresentationOfLeasesForLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases" } } }, "localname": "PresentationOfLeasesForLesseeAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities": { "auth_ref": [ "r199" ], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from borrowings obtained. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Proceeds from borrowings, classified as financing activities", "terseLabel": "Proceeds from borrowings" } } }, "localname": "ProceedsFromBorrowingsClassifiedAsFinancingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets": { "auth_ref": [ "r254" ], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from the disposal or maturity of available-for-sale financial assets. [Refer: Financial assets available-for-sale]" } }, "en-us": { "role": { "label": "Proceeds from disposal or maturity of available-for-sale financial assets", "terseLabel": "Maturities of investments" } } }, "localname": "ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProceedsFromIssueOfOrdinaryShares": { "auth_ref": [ "r248" ], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]" } }, "en-us": { "role": { "label": "Proceeds from issue of ordinary shares", "terseLabel": "Proceeds from common shares from initial public offering, net" } } }, "localname": "ProceedsFromIssueOfOrdinaryShares", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesCommonSharesDetails", "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProceedsFromIssueOfPreferenceShares": { "auth_ref": [ "r248" ], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from the issuing of preference shares. [Refer: Preference shares [member]]" } }, "en-us": { "role": { "label": "Proceeds from issue of preference shares", "terseLabel": "Proceeds from Series C financing, net" } } }, "localname": "ProceedsFromIssueOfPreferenceShares", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesPreferenceShareDetails", "http://www.lavatherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfessionalFeesExpense": { "auth_ref": [ "r239" ], "calculation": { "http://www.lavatherapeutics.com/role/DisclosureGeneralAndAdministrativeExpensesDetails": { "order": 2.0, "parentTag": "ifrs-full_GeneralAndAdministrativeExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of fees paid or payable for professional services." } }, "en-us": { "role": { "label": "Professional fees expense", "terseLabel": "Professional and consultant fees" } } }, "localname": "ProfessionalFeesExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureGeneralAndAdministrativeExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLoss": { "auth_ref": [ "r1", "r26", "r82", "r91", "r93", "r166", "r167", "r204", "r220", "r222" ], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Profit (loss)", "terseLabel": "Loss attributable to the parent entity", "totalLabel": "Loss for the year", "verboseLabel": "Loss for the period" } } }, "localname": "ProfitLoss", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureEarningsPerShareEpsDetails", "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity", "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossBeforeTax": { "auth_ref": [ "r144", "r186", "r187", "r218", "r219" ], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 }, "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Profit (loss) before tax", "terseLabel": "Loss before income tax", "totalLabel": "Loss before income tax" } } }, "localname": "ProfitLossBeforeTax", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossFromOperatingActivities": { "auth_ref": [ "r195", "r245" ], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Profit (loss) from operating activities", "totalLabel": "Operating loss" } } }, "localname": "ProfitLossFromOperatingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PropertyPlantAndEquipment": { "auth_ref": [ "r7", "r42" ], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPositions": { "order": 1.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period." } }, "en-us": { "role": { "label": "Property, plant and equipment", "periodEndLabel": "Balance, at end of the period", "periodStartLabel": "Balance, at beginning of the period", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipment", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosurePropertyAndEquipmentDetails", "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PropertyPlantAndEquipmentMember": { "auth_ref": [ "r43", "r196", "r212" ], "lang": { "en": { "role": { "documentation": "This member stands for property, plant and equipment. It also represents the standard value for the 'Classes of property, plant and equipment' axis if no other member is used. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Property, plant and equipment [member]" } } }, "localname": "PropertyPlantAndEquipmentMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosurePropertyAndEquipmentDetails", "http://www.lavatherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ProportionOfOwnershipInterestInSubsidiary": { "auth_ref": [ "r61", "r63", "r94" ], "lang": { "en": { "role": { "documentation": "The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]" } }, "en-us": { "role": { "label": "Proportion of ownership interest in subsidiary", "terseLabel": "Proportion of ownership interest in subsidiary" } } }, "localname": "ProportionOfOwnershipInterestInSubsidiary", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureCorporateAndCompanyInformationDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_PurchaseOfAvailableforsaleFinancialAssets": { "auth_ref": [ "r254" ], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for the purchase of available-for-sale financial assets. [Refer: Financial assets available-for-sale]" } }, "en-us": { "role": { "label": "Purchase of available-for-sale financial assets", "negatedLabel": "Purchases of investments" } } }, "localname": "PurchaseOfAvailableforsaleFinancialAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": { "auth_ref": [ "r197" ], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Purchase of property, plant and equipment, classified as investing activities", "negatedLabel": "Purchase of property and equipment" } } }, "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PurchaseOfTreasuryShares": { "auth_ref": [ "r237" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The decrease in equity resulting from the purchase of treasury shares. [Refer: Treasury shares]" } }, "en-us": { "role": { "label": "Purchase of treasury shares", "negatedLabel": "Series A Preferred and common shares repurchase" } } }, "localname": "PurchaseOfTreasuryShares", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RangeAxis": { "auth_ref": [ "r109", "r138", "r175", "r206", "r208", "r253" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Range [axis]" } } }, "localname": "RangeAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureRelatedPartiesDirectorAndShareholderCompensationDetails", "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationFairValueMeasurementDetails", "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationNarrativesDetails", "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationNumberOfOptionAndExercisePriceDetails", "http://www.lavatherapeutics.com/role/DisclosureTradePayablesAndOtherDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_RangesMember": { "auth_ref": [ "r109", "r138", "r175", "r206", "r208", "r253" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used." } }, "en-us": { "role": { "label": "Ranges [member]" } } }, "localname": "RangesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureRelatedPartiesDirectorAndShareholderCompensationDetails", "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationFairValueMeasurementDetails", "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationNarrativesDetails", "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationNumberOfOptionAndExercisePriceDetails", "http://www.lavatherapeutics.com/role/DisclosureTradePayablesAndOtherDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ResearchAndDevelopmentExpense": { "auth_ref": [ "r74" ], "calculation": { "http://www.lavatherapeutics.com/role/DisclosureResearchAndDevelopmentExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss." } }, "en-us": { "role": { "label": "Research and development expense", "negatedLabel": "Research and development", "totalLabel": "Total research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureResearchAndDevelopmentExpensesDetails", "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ReserveOfExchangeDifferencesOnTranslation": { "auth_ref": [ "r48" ], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPositions": { "order": 4.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "A component of equity representing exchange differences on translation of financial statements recognised in other comprehensive income and accumulated in equity. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Reserve of exchange differences on translation", "terseLabel": "Foreign currency translation reserve" } } }, "localname": "ReserveOfExchangeDifferencesOnTranslation", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember": { "auth_ref": [ "r48", "r188" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing accumulated exchange differences on the translation of financial statements recognised in other comprehensive income. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Foreign currency translation reserve" } } }, "localname": "ReserveOfExchangeDifferencesOnTranslationMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_RetainedEarnings": { "auth_ref": [ "r189", "r190" ], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPositions": { "order": 5.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit." } }, "en-us": { "role": { "label": "Retained earnings", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarnings", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RetainedEarningsMember": { "auth_ref": [ "r3", "r188" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit." } }, "en-us": { "role": { "label": "Accumulated losses" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_RevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue [abstract]", "terseLabel": "Revenue:" } } }, "localname": "RevenueAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "xbrltype": "stringItemType" }, "ifrs-full_RevenueFromContractsWithCustomers": { "auth_ref": [ "r111", "r112" ], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity\u2019s ordinary activities in exchange for consideration." } }, "en-us": { "role": { "label": "Revenue from contracts with customers", "terseLabel": "Research and license revenue", "verboseLabel": "Revenue" } } }, "localname": "RevenueFromContractsWithCustomers", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureRevenueDetails", "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RightofuseAssets": { "auth_ref": [ "r123" ], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPositions": { "order": 2.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee." } }, "en-us": { "role": { "label": "Right-of-use assets", "periodEndLabel": "Balance at Ending", "periodStartLabel": "Balance at beginning", "terseLabel": "Right-of-use assets" } } }, "localname": "RightofuseAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureLeasesDetails", "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ServicesReceivedRelatedPartyTransactions": { "auth_ref": [ "r194" ], "calculation": { "http://www.lavatherapeutics.com/role/DisclosureRelatedPartiesDirectorAndShareholderCompensationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of services received in related party transactions. [Refer: Related parties [member]]" } }, "en-us": { "role": { "label": "Services received, related party transactions", "totalLabel": "Total director and shareholder compensation" } } }, "localname": "ServicesReceivedRelatedPartyTransactions", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureRelatedPartiesDirectorAndShareholderCompensationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ShareIssueRelatedCost": { "auth_ref": [ "r237" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of cost related to the issuance of shares." } }, "en-us": { "role": { "label": "Share issue related cost", "terseLabel": "Issuance costs" } } }, "localname": "ShareIssueRelatedCost", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesCommonSharesDetails", "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesPreferenceShareDetails", "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquityParenthetical" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SharePremium": { "auth_ref": [ "r189" ], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPositions": { "order": 2.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value." } }, "en-us": { "role": { "label": "Share premium.", "terseLabel": "Share premium" } } }, "localname": "SharePremium", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesSummaryDetails", "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SharePremiumMember": { "auth_ref": [ "r3" ], "lang": { "en": { "role": { "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value." } }, "en-us": { "role": { "label": "Share premium" } } }, "localname": "SharePremiumMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents": { "auth_ref": [ "r252" ], "calculation": { "http://www.lavatherapeutics.com/role/DisclosureCashAndCashEquivalentsDetails": { "order": 1.0, "parentTag": "ifrs-full_CashAndCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]" } }, "en-us": { "role": { "label": "Short-term deposits, classified as cash equivalents", "terseLabel": "Short-term deposits" } } }, "localname": "ShorttermDepositsClassifiedAsCashEquivalents", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureCashAndCashEquivalentsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SignificantInvestmentsInSubsidiariesAxis": { "auth_ref": [ "r62", "r64", "r103" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Subsidiaries [axis]" } } }, "localname": "SignificantInvestmentsInSubsidiariesAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureCorporateAndCompanyInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consolidated statements of cash flows" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_StatementOfChangesInEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consolidated statements of changes in equity" } } }, "localname": "StatementOfChangesInEquityAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_StatementOfChangesInEquityLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Statement of changes in equity [line items]", "terseLabel": "Consolidated statements of changes in equity" } } }, "localname": "StatementOfChangesInEquityLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity", "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquityParenthetical" ], "xbrltype": "stringItemType" }, "ifrs-full_StatementOfChangesInEquityTable": { "auth_ref": [ "r3" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to changes in equity." } }, "en-us": { "role": { "label": "Statement of changes in equity [table]" } } }, "localname": "StatementOfChangesInEquityTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity", "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquityParenthetical" ], "xbrltype": "stringItemType" }, "ifrs-full_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consolidated statements of financial position" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_StatementOfProfitOrLossAndOtherComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consolidated statements of loss and other comprehensive loss" } } }, "localname": "StatementOfProfitOrLossAndOtherComprehensiveIncomeAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_TemporaryDifferenceMember": { "auth_ref": [ "r35" ], "lang": { "en": { "role": { "documentation": "This member stands for differences between the carrying amount of an asset or liability in the statement of financial position and its tax base. Temporary differences may be either: (a) taxable temporary differences; or (b) deductible temporary differences. [Refer: Carrying amount [member]]" } }, "en-us": { "role": { "label": "Accounting-to-tax differences" } } }, "localname": "TemporaryDifferenceMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureTaxationTaxLossesCarryForwardDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis": { "auth_ref": [ "r35" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Temporary difference, unused tax losses and unused tax credits [axis]" } } }, "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureTaxationTaxLossesCarryForwardDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember": { "auth_ref": [ "r35" ], "lang": { "en": { "role": { "documentation": "This member stands for temporary differences, unused tax losses and unused tax credits. It also represents the standard value for the 'Temporary difference, unused tax losses and unused tax credits' axis if no other member is used. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]" } }, "en-us": { "role": { "label": "Temporary difference, unused tax losses and unused tax credits [member]" } } }, "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureTaxationTaxLossesCarryForwardDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_TopOfRangeMember": { "auth_ref": [ "r109", "r138", "r175", "r206", "r208", "r253" ], "lang": { "en": { "role": { "documentation": "This member stands for top of a range." } }, "en-us": { "role": { "label": "Top of range" } } }, "localname": "TopOfRangeMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationFairValueMeasurementDetails", "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationNarrativesDetails", "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationNumberOfOptionAndExercisePriceDetails", "http://www.lavatherapeutics.com/role/DisclosureTradePayablesAndOtherDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_TradeAndOtherCurrentPayables": { "auth_ref": [ "r10" ], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPositions": { "order": 1.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]" } }, "en-us": { "role": { "label": "Trade and other current payables", "terseLabel": "Trade payables and other" } } }, "localname": "TradeAndOtherCurrentPayables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureTradePayablesAndOtherDetails", "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TradeAndOtherCurrentReceivables": { "auth_ref": [ "r8", "r17" ], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPositions": { "order": 1.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]" } }, "en-us": { "role": { "label": "Trade and other current receivables", "terseLabel": "Receivables and other" } } }, "localname": "TradeAndOtherCurrentReceivables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TradeAndOtherPayablesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Trade payables and other." } } }, "localname": "TradeAndOtherPayablesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_TypesOfRisksAxis": { "auth_ref": [ "r145", "r149", "r150", "r176", "r177", "r178", "r180" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Types of risks [axis]" } } }, "localname": "TypesOfRisksAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureFinancialInstrumentsRiskManagementAndCapitalManagementDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_TypesOfRisksMember": { "auth_ref": [ "r145", "r149", "r150", "r176", "r177", "r178", "r180" ], "lang": { "en": { "role": { "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used." } }, "en-us": { "role": { "label": "Risks [member]" } } }, "localname": "TypesOfRisksMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureFinancialInstrumentsRiskManagementAndCapitalManagementDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised": { "auth_ref": [ "r33" ], "lang": { "en": { "role": { "documentation": "The amount of unused tax losses for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax losses [member]]" } }, "en-us": { "role": { "label": "Unused tax losses for which no deferred tax asset recognised", "terseLabel": "Tax loss carryforwards" } } }, "localname": "UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureTaxationDetails", "http://www.lavatherapeutics.com/role/DisclosureTaxationTaxLossesCarryForwardDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment": { "auth_ref": [ "r37" ], "lang": { "en": { "role": { "documentation": "The useful life, measured as period of time, used for property, plant and equipment. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Useful life measured as period of time, property, plant and equipment", "terseLabel": "Estimated useful lives" } } }, "localname": "UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "durationItemType" }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019": { "auth_ref": [ "r133" ], "lang": { "en": { "role": { "documentation": "The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average exercise price of share options exercised in share-based payment arrangement", "terseLabel": "Exercised, Weighted average exercise price" } } }, "localname": "WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationNumberOfOptionAndExercisePriceDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019": { "auth_ref": [ "r132" ], "lang": { "en": { "role": { "documentation": "The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average exercise price of share options granted in share-based payment arrangement", "terseLabel": "Granted, Weighted average exercise price", "verboseLabel": "Number of weighted average exercise price" } } }, "localname": "WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationNarrativesDetails", "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationNumberOfOptionAndExercisePriceDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019": { "auth_ref": [ "r131", "r134" ], "lang": { "en": { "role": { "documentation": "The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average exercise price of share options outstanding in share-based payment arrangement", "periodEndLabel": "Outstanding at ending, Weighted average exercise price", "periodStartLabel": "Outstanding at Beginning, Weighted average exercise price" } } }, "localname": "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationNumberOfOptionAndExercisePriceDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted": { "auth_ref": [ "r141" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The weighted average fair value of share options granted during the period at the measurement date. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average fair value at measurement date, share options granted", "terseLabel": "Weighted average grant date fair value" } } }, "localname": "WeightedAverageFairValueAtMeasurementDateShareOptionsGranted", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationFairValueMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16": { "auth_ref": [ "r127" ], "lang": { "en": { "role": { "documentation": "The weighted average lessee's incremental borrowing rate applied to lease liabilities recognised in the statement of financial position at the date of initial application of IFRS 16. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of a similar value to the right-of-use asset in a similar economic environment." } }, "en-us": { "role": { "label": "Weighted average lessee's incremental borrowing rate applied to lease liabilities recognised at date of initial application of IFRS 16", "terseLabel": "Average incremental borrowing rate applied to the lease liabilities" } } }, "localname": "WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019": { "auth_ref": [ "r138" ], "lang": { "en": { "role": { "documentation": "The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average remaining contractual life of outstanding share options", "terseLabel": "Outstanding, Weighted average remaining contractual term" } } }, "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationNumberOfOptionAndExercisePriceDetails" ], "xbrltype": "durationItemType" }, "ifrs-full_WeightedAverageSharePrice2019": { "auth_ref": [ "r137" ], "lang": { "en": { "role": { "documentation": "The weighted average share price. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average share price", "terseLabel": "Stock issued price per share" } } }, "localname": "WeightedAverageSharePrice2019", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquityParenthetical" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019": { "auth_ref": [ "r140" ], "lang": { "en": { "role": { "documentation": "The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average share price, share options granted", "terseLabel": "Fair value of the common share" } } }, "localname": "WeightedAverageSharePriceShareOptionsGranted2019", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationFairValueMeasurementDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageShares": { "auth_ref": [ "r67" ], "lang": { "en": { "role": { "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor." } }, "en-us": { "role": { "label": "Weighted average number of ordinary shares used in calculating basic earnings per share", "terseLabel": "Weighted average common shares outstanding, basic" } } }, "localname": "WeightedAverageShares", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureEarningsPerShareEpsDetails", "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "xbrltype": "sharesItemType" }, "lvtx_AccruedExpensesAndOtherCurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for accrued expenses and other current liabilities.", "label": "Accrued expenses and other current liabilities" } } }, "localname": "AccruedExpensesAndOtherCurrentLiabilitiesMember", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureFinancialInstrumentsRiskManagementAndCapitalManagementDetails" ], "xbrltype": "domainItemType" }, "lvtx_AdjustmentForAmortizationOfPremiumOnInvestments": { "auth_ref": [], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustments for amortization of premium on investments to reconcile profit (loss) to net cash flow from (used in) operating activities.", "label": "Adjustment for Amortization of Premium on Investments", "terseLabel": "Amortization of premium on investments" } } }, "localname": "AdjustmentForAmortizationOfPremiumOnInvestments", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "lvtx_AdjustmentsForDepreciationAndAmortisationExpenseOfRightOfUseAssets": { "auth_ref": [], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustments for depreciation and amortisation expense of right of use assets to reconcile profit (loss) to net cash flow from (used in) operating activities.", "label": "Adjustments For Depreciation And Amortisation Expense Of Right Of Use Assets", "terseLabel": "Depreciation and amortization of right-of-use assets" } } }, "localname": "AdjustmentsForDepreciationAndAmortisationExpenseOfRightOfUseAssets", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "lvtx_AdjustmentsForIncreaseDecreaseInDeferredOfferingCosts": { "auth_ref": [], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustments for increase (decrease) in deferred offering costs to reconcile profit (loss) to net cash flow from (used in) operating activities.", "label": "Adjustments For Increase (Decrease) In Deferred Offering Costs", "terseLabel": "Deferred offering costs" } } }, "localname": "AdjustmentsForIncreaseDecreaseInDeferredOfferingCosts", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "lvtx_AdjustmentsForIncreaseDecreaseInResearchAndDevelopmentLicenseLiabilities": { "auth_ref": [], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustments for increase (decrease) in research and development license liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities.", "label": "Adjustments For Increase Decrease In Research and Development, License Liabilities", "terseLabel": "License liabilities" } } }, "localname": "AdjustmentsForIncreaseDecreaseInResearchAndDevelopmentLicenseLiabilities", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "lvtx_AdjustmentsForIncreaseDecreaseInValueAddedTaxReceivable": { "auth_ref": [], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustments for increase decrease in value added tax receivable to reconcile profit (loss) to net cash flow from (used in) operating activities.", "label": "Adjustments For Increase (Decrease) In Value Added Tax Receivable", "negatedLabel": "VAT receivable" } } }, "localname": "AdjustmentsForIncreaseDecreaseInValueAddedTaxReceivable", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "lvtx_AverageCreditPeriodOnDomesticPurchasesOfCertainGoods": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the average credit period on domestic purchases of certain goods.", "label": "Average Credit Period on Domestic Purchases of Certain Goods", "terseLabel": "Average credit period on domestic purchases of certain goods" } } }, "localname": "AverageCreditPeriodOnDomesticPurchasesOfCertainGoods", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureTradePayablesAndOtherDetails" ], "xbrltype": "durationItemType" }, "lvtx_CashAndCashEquivalentsAndCurrentInvestments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and current investments.", "label": "Cash and Cash Equivalents and Current Investments", "terseLabel": "Cash, cash equivalents and investments" } } }, "localname": "CashAndCashEquivalentsAndCurrentInvestments", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "lvtx_CashAndCashEquivalentsPercentageHeldWithLargeWellKnownInstitutions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of cash and cash equivalents held with large, well known institutions.", "label": "Cash And Cash Equivalents, Percentage Held With Large, Well Known Institutions", "terseLabel": "Percentage of cash and cash equivalents held with large, well known institutions" } } }, "localname": "CashAndCashEquivalentsPercentageHeldWithLargeWellKnownInstitutions", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureFinancialInstrumentsRiskManagementAndCapitalManagementDetails" ], "xbrltype": "percentItemType" }, "lvtx_ChangesInWorkingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Changes In Working Capital [Abstract]", "terseLabel": "Changes in working capital:" } } }, "localname": "ChangesInWorkingCapitalAbstract", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "lvtx_CorporateInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Corporate and Company information" } } }, "localname": "CorporateInformationAbstract", "nsuri": "http://www.lavatherapeutics.com/20211231", "xbrltype": "stringItemType" }, "lvtx_CurrentLicenseLiabilitiesResearchAndDevelopment": { "auth_ref": [], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPositions": { "order": 5.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of current license liabilities related to research and development.", "label": "Current License Liabilities, Research and Development", "terseLabel": "License liabilities" } } }, "localname": "CurrentLicenseLiabilitiesResearchAndDevelopment", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "lvtx_DeferredOfferingCostsCurrent": { "auth_ref": [], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPositions": { "order": 3.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of deferred offering costs classified as current.", "label": "Deferred Offering Costs, Current", "terseLabel": "Deferred offering costs" } } }, "localname": "DeferredOfferingCostsCurrent", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "lvtx_DeferredOfferingCostsInAccountsPayableAndAccruedExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred offering costs in accounts payable and accrued expenses.", "label": "Deferred Offering Costs In Accounts Payable And Accrued Expenses", "terseLabel": "Deferred offering costs in accounts payable and accrued expenses" } } }, "localname": "DeferredOfferingCostsInAccountsPayableAndAccruedExpenses", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "lvtx_DescriptionOfAccountingPolicyForGeneralAndAdministrationExpensePolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The description of the entity's accounting policy for general and administrative expenses.", "label": "Description Of Accounting Policy For General And Administration Expense [Policy Text Block]", "terseLabel": "General and administrative expenses" } } }, "localname": "DescriptionOfAccountingPolicyForGeneralAndAdministrationExpensePolicyTextBlock", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "lvtx_DirectorsBoardFees": { "auth_ref": [], "calculation": { "http://www.lavatherapeutics.com/role/DisclosureRelatedPartiesDirectorAndShareholderCompensationDetails": { "order": 2.0, "parentTag": "ifrs-full_ServicesReceivedRelatedPartyTransactions", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses for directors board fees.", "label": "Directors Board Fees", "terseLabel": "Board fees" } } }, "localname": "DirectorsBoardFees", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureRelatedPartiesDirectorAndShareholderCompensationDetails" ], "xbrltype": "monetaryItemType" }, "lvtx_DisclosureOfDetailedInformationAboutIncomeTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "n/a.", "label": "Taxation" } } }, "localname": "DisclosureOfDetailedInformationAboutIncomeTaxAbstract", "nsuri": "http://www.lavatherapeutics.com/20211231", "xbrltype": "stringItemType" }, "lvtx_DisclosureOfInterestExpensesExplanatoryTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of interest expenses.", "label": "Disclosure of Interest Expenses Explanatory [Table Text Block]", "terseLabel": "Schedule of interest expenses" } } }, "localname": "DisclosureOfInterestExpensesExplanatoryTableTextBlock", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureInterestExpenseNetTables" ], "xbrltype": "textBlockItemType" }, "lvtx_DisclosureOfMaturityAnalysisOfLeasePaymentsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of a maturity analysis of finance lease payments .", "label": "Disclosure of maturity analysis of lease payments [text block]", "terseLabel": "Schedule of maturities of lease liabilities" } } }, "localname": "DisclosureOfMaturityAnalysisOfLeasePaymentsTextBlock", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "lvtx_DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of estimated useful lives of property, plant, and equipment.", "label": "Disclosure Of Property Plant And Equipment Estimated Useful Life [Table Text Block]", "terseLabel": "Schedule of estimated useful lives" } } }, "localname": "DisclosureOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "lvtx_DisclosureOfTaxLossCarryforwardExpiryExplanatoryTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of tax loss carryforward expiry disclosure.", "label": "Disclosure of Tax Loss carryforward Expiry, Explanatory [Table Text Block]", "terseLabel": "Schedule of tax-losses incurred" } } }, "localname": "DisclosureOfTaxLossCarryforwardExpiryExplanatoryTableTextBlock", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureTaxationTables" ], "xbrltype": "textBlockItemType" }, "lvtx_ForeignCurrencyTranslationAdjustment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The equity impact of the foreign currency translation adjustment.", "label": "Foreign Currency Translation Adjustment", "terseLabel": "Foreign currency translation adjustment" } } }, "localname": "ForeignCurrencyTranslationAdjustment", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "lvtx_GeneralAndAdministrativeExpenseInsuranceFacilitiesFeesAndOtherRelatedCosts": { "auth_ref": [], "calculation": { "http://www.lavatherapeutics.com/role/DisclosureGeneralAndAdministrativeExpensesDetails": { "order": 4.0, "parentTag": "ifrs-full_GeneralAndAdministrativeExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of insurance, facilities, fees, and other related costs relating to general and administrative activities of the entity.", "label": "General And Administrative Expense, Insurance, Facilities, Fees And Other Related Costs", "terseLabel": "Insurance, facilities, fees and other related costs" } } }, "localname": "GeneralAndAdministrativeExpenseInsuranceFacilitiesFeesAndOtherRelatedCosts", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureGeneralAndAdministrativeExpensesDetails" ], "xbrltype": "monetaryItemType" }, "lvtx_GeneralAndAdministrativeExpensePersonnelRelatedExpenses": { "auth_ref": [], "calculation": { "http://www.lavatherapeutics.com/role/DisclosureGeneralAndAdministrativeExpensesDetails": { "order": 1.0, "parentTag": "ifrs-full_GeneralAndAdministrativeExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of personnel-related expenses relating to general and administrative activities of the entity.", "label": "General And Administrative Expense, Personnel Related Expenses", "terseLabel": "Personnel-related expenses" } } }, "localname": "GeneralAndAdministrativeExpensePersonnelRelatedExpenses", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureGeneralAndAdministrativeExpensesDetails" ], "xbrltype": "monetaryItemType" }, "lvtx_GeneralAndAdministrativeExpenseShareBasedCompensationExpense": { "auth_ref": [], "calculation": { "http://www.lavatherapeutics.com/role/DisclosureGeneralAndAdministrativeExpensesDetails": { "order": 3.0, "parentTag": "ifrs-full_GeneralAndAdministrativeExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of share-based compensation expense relating to general and administrative activities of the entity.", "label": "General And Administrative Expense, Share Based Compensation Expense", "terseLabel": "Share-based compensation expense" } } }, "localname": "GeneralAndAdministrativeExpenseShareBasedCompensationExpense", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureGeneralAndAdministrativeExpensesDetails" ], "xbrltype": "monetaryItemType" }, "lvtx_GeneralAndAdministrativeExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "General and administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpensesAbstract", "nsuri": "http://www.lavatherapeutics.com/20211231", "xbrltype": "stringItemType" }, "lvtx_GildeHealthcareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Gilde Healthcare.", "label": "Gilde Healthcare [Member]", "terseLabel": "Gilde Healthcare" } } }, "localname": "GildeHealthcareMember", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesMajorShareholdersDetails" ], "xbrltype": "domainItemType" }, "lvtx_IFrsPlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "I(frs Plan Name [Domain]" } } }, "localname": "IFrsPlanNameDomain", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationNumberOfOptionAndExercisePriceDetails" ], "xbrltype": "domainItemType" }, "lvtx_IfrsAccruedProfessionalFeesCurrent": { "auth_ref": [], "calculation": { "http://www.lavatherapeutics.com/role/DisclosureWorkingCapitalAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": 3.0, "parentTag": "ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Ifrs Accrued Professional Fees, Current", "terseLabel": "Professional fees" } } }, "localname": "IfrsAccruedProfessionalFeesCurrent", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureWorkingCapitalAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "lvtx_IfrsBorrowingsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Obligations to pay to another in accordance with an expressed or implied agreement.", "label": "Borrowings" } } }, "localname": "IfrsBorrowingsMember", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureFinancialInstrumentsRiskManagementAndCapitalManagementDetails" ], "xbrltype": "domainItemType" }, "lvtx_IfrsBuildingImprovementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to building improvements.\"", "label": "Building improvements" } } }, "localname": "IfrsBuildingImprovementsMember", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosurePropertyAndEquipmentDetails", "http://www.lavatherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "lvtx_IfrsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and cash equivalents" } } }, "localname": "IfrsCashAndCashEquivalentsMember", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureFinancialInstrumentsRiskManagementAndCapitalManagementDetails" ], "xbrltype": "domainItemType" }, "lvtx_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "IFRS Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.lavatherapeutics.com/role/DisclosureRevenueDetails" ], "xbrltype": "stringItemType" }, "lvtx_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "IFRS Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.lavatherapeutics.com/role/DisclosureRevenueDetails" ], "xbrltype": "domainItemType" }, "lvtx_IfrsDeferredOfferingCosts": { "auth_ref": [], "calculation": { "http://www.lavatherapeutics.com/role/DisclosureWorkingCapitalAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": 4.0, "parentTag": "ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.", "label": "Ifrs Deferred Offering Costs", "terseLabel": "Deferred offering costs" } } }, "localname": "IfrsDeferredOfferingCosts", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureWorkingCapitalAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "lvtx_IfrsNumberOfReportableSegments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "IFRS Number of Reportable Segments", "terseLabel": "Number of reportable segment" } } }, "localname": "IfrsNumberOfReportableSegments", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "integerItemType" }, "lvtx_IfrsOverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.", "label": "Over-Allotment Option" } } }, "localname": "IfrsOverAllotmentOptionMember", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesCommonSharesDetails", "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "lvtx_IfrsPlanNameAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Ifrs Plan Name [Axis]" } } }, "localname": "IfrsPlanNameAxis", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationNumberOfOptionAndExercisePriceDetails" ], "xbrltype": "stringItemType" }, "lvtx_IfrsPrepaidInterest": { "auth_ref": [], "calculation": { "http://www.lavatherapeutics.com/role/DisclosureWorkingCapitalAccruedExpensesAndOtherCurrentLiabilitiesDetailss": { "order": 1.0, "parentTag": "ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for interest that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Ifrs Prepaid Interest", "terseLabel": "Prepaid interest on investments" } } }, "localname": "IfrsPrepaidInterest", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureWorkingCapitalPrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "lvtx_IfrsSaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Ifrs Sale of Stock [Axis]" } } }, "localname": "IfrsSaleOfStockAxis", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesCommonSharesDetails", "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity", "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquityParenthetical" ], "xbrltype": "stringItemType" }, "lvtx_IfrsSaleOfStockDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Ifrs Sale of Stock [Domain]" } } }, "localname": "IfrsSaleOfStockDomain", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesCommonSharesDetails", "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity", "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquityParenthetical" ], "xbrltype": "domainItemType" }, "lvtx_IfrsScheduleOfCashAndCashEquivalentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of cash and cash equivalents.", "label": "Ifrs Schedule of Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Schedule of cash and cash equivalents" } } }, "localname": "IfrsScheduleOfCashAndCashEquivalentsTableTextBlock", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureCashAndCashEquivalentsTables" ], "xbrltype": "textBlockItemType" }, "lvtx_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Ifrs Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Vesting period" } } }, "localname": "IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationNarrativesDetails" ], "xbrltype": "durationItemType" }, "lvtx_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Ifrs Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Vesting percentage" } } }, "localname": "IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationNarrativesDetails" ], "xbrltype": "percentItemType" }, "lvtx_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsRemaningPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of vesting of remaining award under share-based payment arrangement.", "label": "Ifrs Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights Remaning Percentage", "terseLabel": "Vesting percentage of remaining awards" } } }, "localname": "IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsRemaningPercentage", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationNarrativesDetails" ], "xbrltype": "percentItemType" }, "lvtx_IfrsShareBasedPaymentArrangementTrancheOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Vesting schemes one" } } }, "localname": "IfrsShareBasedPaymentArrangementTrancheOneMember", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationNarrativesDetails" ], "xbrltype": "domainItemType" }, "lvtx_IfrsShareBasedPaymentArrangementTrancheThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Vesting schemes three" } } }, "localname": "IfrsShareBasedPaymentArrangementTrancheThreeMember", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationNarrativesDetails" ], "xbrltype": "domainItemType" }, "lvtx_IfrsShareBasedPaymentArrangementTrancheTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Vesting schemes two" } } }, "localname": "IfrsShareBasedPaymentArrangementTrancheTwoMember", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationNarrativesDetails" ], "xbrltype": "domainItemType" }, "lvtx_IfrsShareIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issue price per share of stock.", "label": "Ifrs Share Issued, Price Per Share", "terseLabel": "Issue price" } } }, "localname": "IfrsShareIssuedPricePerShare", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesCommonSharesDetails", "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesPreferenceShareDetails" ], "xbrltype": "perShareItemType" }, "lvtx_IfrsStockIssued": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Ifrs Stock Issued", "terseLabel": "Issuance of 235,664 common shares to VUmc in lieu of payment for license liabilities" } } }, "localname": "IfrsStockIssued", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "lvtx_IfrsStockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period, Shares, New Issues", "label": "IFRS Stock Issued During Period, Shares, New Issues", "terseLabel": "Shares issued" } } }, "localname": "IfrsStockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesPreferenceShareDetails" ], "xbrltype": "sharesItemType" }, "lvtx_IfrsTaxPeriodAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines tax periods.", "label": "Ifrs Tax Period [Axis]" } } }, "localname": "IfrsTaxPeriodAxis", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureTaxationTaxLossesCarryForwardDetails" ], "xbrltype": "stringItemType" }, "lvtx_IfrsTaxPeriodDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The domain of a table defines tax periods.", "label": "Ifrs Tax Period [Domain]" } } }, "localname": "IfrsTaxPeriodDomain", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureTaxationTaxLossesCarryForwardDetails" ], "xbrltype": "domainItemType" }, "lvtx_IfrsVestingAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Axis]" } } }, "localname": "IfrsVestingAxis", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationNarrativesDetails", "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesPreferenceShareDetails" ], "xbrltype": "stringItemType" }, "lvtx_IfrsVestingDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Domain]" } } }, "localname": "IfrsVestingDomain", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationNarrativesDetails", "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesPreferenceShareDetails" ], "xbrltype": "domainItemType" }, "lvtx_Ifrs_operatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Operating expenses:", "terseLabel": "Operating expenses:" } } }, "localname": "Ifrs_operatingExpensesAbstract", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "xbrltype": "stringItemType" }, "lvtx_IncreaseDecreaseThroughConversionOfConvertibleInstrumentsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in number of shares resulting from conversion of convertible instruments.", "label": "Increase (Decrease) Through Conversion Of Convertible Instruments, Shares", "terseLabel": "Conversion of preference shares (in shares)" } } }, "localname": "IncreaseDecreaseThroughConversionOfConvertibleInstrumentsShares", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "sharesItemType" }, "lvtx_IncreaseDecreaseThroughForeignCurrencyTranslationDifferenceContractLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in contract liabilities resulting from foreign currency translation difference.", "label": "Increase Decrease Through Foreign Currency Translation Difference, Contract Liabilities", "negatedLabel": "Foreign currency translation difference" } } }, "localname": "IncreaseDecreaseThroughForeignCurrencyTranslationDifferenceContractLiabilities", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureRevenueDetails" ], "xbrltype": "monetaryItemType" }, "lvtx_IncreaseDecreaseThroughIssuanceOfEquityInLieuOfLicenseLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in equity resulting from equity issued in lieu of license liability.", "label": "Increase Decrease Through Issuance Of Equity in Lieu of License Liability", "terseLabel": "Amount of increase (decrease) in lieu of equity license liability" } } }, "localname": "IncreaseDecreaseThroughIssuanceOfEquityInLieuOfLicenseLiability", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesCommonSharesDetails" ], "xbrltype": "monetaryItemType" }, "lvtx_IncreaseDecreaseThroughIssuanceOfEquityShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued Increase decrease through issuance of equity shares.", "label": "Increase Decrease Through Issuance Of Equity Shares", "terseLabel": "Number of shares issued and sold" } } }, "localname": "IncreaseDecreaseThroughIssuanceOfEquityShares", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesCommonSharesDetails" ], "xbrltype": "sharesItemType" }, "lvtx_IncreaseDecreaseThroughIssueOfEquityInLieuOfLicenseLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in equity resulting from equity issued in lieu of license liability.", "label": "Increase Decrease Through Issue Of Equity in Lieu of License Liability", "terseLabel": "Issuance of VUmc common stock" } } }, "localname": "IncreaseDecreaseThroughIssueOfEquityInLieuOfLicenseLiability", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "lvtx_IncreaseDecreaseThroughIssueOfEquityShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in number of shares resulting from issue of equity.", "label": "Increase (Decrease) Through Issue OF Equity, Shares", "terseLabel": "Issuance of stock (in shares)" } } }, "localname": "IncreaseDecreaseThroughIssueOfEquityShares", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "sharesItemType" }, "lvtx_IncreaseDecreaseThroughTreasuryShareTransactionsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in number of shares resulting from treasury share transactions.", "label": "Increase (Decrease) Through Treasury Share Transactions, Shares", "terseLabel": "Series A Preferred and common shares repurchase (in shares)" } } }, "localname": "IncreaseDecreaseThroughTreasuryShareTransactionsShares", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "sharesItemType" }, "lvtx_IncrementalDiscountRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Incremental discount rate to measure lack of marketability of options granted.", "label": "Incremental Discount Rate", "terseLabel": "Incremental discount rate" } } }, "localname": "IncrementalDiscountRate", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationNarrativesDetails" ], "xbrltype": "percentItemType" }, "lvtx_InnovationBoxTaxRatePercentagePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of Innovation box tax rate.", "label": "Innovation Box Tax Rate, Percentage Percentage", "terseLabel": "Effective rate for Innovation Box profits" } } }, "localname": "InnovationBoxTaxRatePercentagePercentage", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureTaxationTaxLossesCarryForwardDetails" ], "xbrltype": "percentItemType" }, "lvtx_InnovationCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for innovation credit.", "label": "Innovation Credit [Member]", "terseLabel": "Innovation Credit" } } }, "localname": "InnovationCreditMember", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureBorrowingsDetails" ], "xbrltype": "domainItemType" }, "lvtx_InvestmentsInDebtSecuritiesPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The description of the entity's accounting policy for investments in debt securities.", "label": "Investments in Debt Securities Policy [Policy Text Block]", "terseLabel": "Investments" } } }, "localname": "InvestmentsInDebtSecuritiesPolicyPolicyTextBlock", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "lvtx_IpoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "IPO" } } }, "localname": "IpoMember", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesCommonSharesDetails", "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity", "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquityParenthetical" ], "xbrltype": "domainItemType" }, "lvtx_JanssenBiotechincMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Janssen Biotech Inc.", "label": "Janssen Biotech Inc [Member]", "terseLabel": "Janssen Biotech Inc" } } }, "localname": "JanssenBiotechincMember", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureRevenueDetails" ], "xbrltype": "domainItemType" }, "lvtx_LaboratoryEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing laboratory equipment used to support office functions, not specifically used in the production process.", "label": "Laboratory Equipment [Member]", "terseLabel": "Laboratory equipment" } } }, "localname": "LaboratoryEquipmentMember", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosurePropertyAndEquipmentDetails", "http://www.lavatherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "lvtx_LavaTherapeuticsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Lava Therapeutics INC.", "label": "Lava Therapeutics INC" } } }, "localname": "LavaTherapeuticsIncMember", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureCorporateAndCompanyInformationDetails" ], "xbrltype": "domainItemType" }, "lvtx_LavaTherapeuticsN.v.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Lava Therapeutics N.V.", "label": "Lava Therapeutics N.V." } } }, "localname": "LavaTherapeuticsN.v.Member", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureCorporateAndCompanyInformationDetails" ], "xbrltype": "domainItemType" }, "lvtx_LeaseCommitments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lease commitments.", "label": "Lease Commitments", "terseLabel": "Lease commitment" } } }, "localname": "LeaseCommitments", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "lvtx_LeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [], "calculation": { "http://www.lavatherapeutics.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "lvtx_UndiscountedLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments.", "label": "Lease Liability, Undiscounted Excess Amount.", "negatedLabel": "Less: imputed lease interest" } } }, "localname": "LeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "lvtx_LicenseAndAssignmentAgreementWithVumcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for license and assignment agreement with VUmc.", "label": "VUmc Agreement" } } }, "localname": "LicenseAndAssignmentAgreementWithVumcMember", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "lvtx_LicenseLiabilitiesPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount payable for license liabilities upon first and second anniversary of IPO.", "label": "License Liabilities Payable", "terseLabel": "License liability payable" } } }, "localname": "LicenseLiabilitiesPayable", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "lvtx_LicenseLiabilitiesPayableSharesPriceValuesOnDaysPriorToAnniversaryOfIpo": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License liabilities payables valued using the closing price of shares days prior to anniversary of IPO.", "label": "License Liabilities Payable, Shares Price Values on Days Prior to Anniversary of IPO", "terseLabel": "Number of trading days prior to anniversary of IPO" } } }, "localname": "LicenseLiabilitiesPayableSharesPriceValuesOnDaysPriorToAnniversaryOfIpo", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "integerItemType" }, "lvtx_LongTermIncentiveOptionPlan2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for 2021 long term incentive option plan.", "label": "2021 Long-term Incentive Option Plan" } } }, "localname": "LongTermIncentiveOptionPlan2021Member", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationNumberOfOptionAndExercisePriceDetails" ], "xbrltype": "domainItemType" }, "lvtx_MajorShareholderNameAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table.", "label": "Major Shareholder Name [Axis]" } } }, "localname": "MajorShareholderNameAxis", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesMajorShareholdersDetails" ], "xbrltype": "stringItemType" }, "lvtx_MajorShareholderNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for the major shareholders. It also represents the standard value for the 'Major Shareholder Axis' axis if no other member is used.", "label": "Major Shareholder Name [Domain]" } } }, "localname": "MajorShareholderNameDomain", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesMajorShareholdersDetails" ], "xbrltype": "domainItemType" }, "lvtx_NonCurrentLicenseLiabilitiesResearchAndDevelopment": { "auth_ref": [], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPositions": { "order": 4.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of non-current license liabilities related to research and development.", "label": "Non-current License Liabilities, Research and Development", "terseLabel": "License liabilities" } } }, "localname": "NonCurrentLicenseLiabilitiesResearchAndDevelopment", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "lvtx_NonoperatingExpenses": { "auth_ref": [], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of non-operating expenses incurred during the period.", "label": "Nonoperating Expenses", "negatedTotalLabel": "Total non-operating expenses" } } }, "localname": "NonoperatingExpenses", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfLossAndOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "lvtx_NovoHoldingsASMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Novo Holdings A/S.", "label": "Novo Holdings A/S [Member]", "terseLabel": "Novo Holdings A/S" } } }, "localname": "NovoHoldingsASMember", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesMajorShareholdersDetails" ], "xbrltype": "domainItemType" }, "lvtx_NumberOfRemainingTranches": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of remaining tranches.", "label": "Number Of Remaining Tranches", "terseLabel": "Number of remaining tranches" } } }, "localname": "NumberOfRemainingTranches", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesPreferenceShareDetails", "http://www.lavatherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "integerItemType" }, "lvtx_NumberOfTranches": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of tranches.", "label": "Number of Tranches", "terseLabel": "Number of tranches" } } }, "localname": "NumberOfTranches", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesPreferenceShareDetails" ], "xbrltype": "integerItemType" }, "lvtx_OptionsExercisableTermDuration": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents about exercisable term of options.", "label": "Options Exercisable Term Duration", "terseLabel": "Option exercisable term (in years)" } } }, "localname": "OptionsExercisableTermDuration", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationNarrativesDetails" ], "xbrltype": "durationItemType" }, "lvtx_OtherNonCurrentAssetsAndSecurityDepositsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for other non-current assets and security deposits.", "label": "Other non-current assets and security deposits" } } }, "localname": "OtherNonCurrentAssetsAndSecurityDepositsMember", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureFinancialInstrumentsRiskManagementAndCapitalManagementDetails" ], "xbrltype": "domainItemType" }, "lvtx_OtherNoncurrentAssetsAndSecurityDeposits": { "auth_ref": [], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPositions": { "order": 3.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of non-current assets that the entity does not separately disclose in the same statement or note and security deposits.", "label": "Other Noncurrent Assets And Security Deposits", "terseLabel": "Other non-current assets and security deposits" } } }, "localname": "OtherNoncurrentAssetsAndSecurityDeposits", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "lvtx_OtherShareholdersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Other shareholders.", "label": "Other Shareholders [Member]", "terseLabel": "Other shareholders" } } }, "localname": "OtherShareholdersMember", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesMajorShareholdersDetails" ], "xbrltype": "domainItemType" }, "lvtx_PaymentMadeForLicenseLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for payment of license liability.", "label": "Payment Made for License Liabilities", "terseLabel": "Payment of license liability" } } }, "localname": "PaymentMadeForLicenseLiabilities", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "lvtx_PercentageOfIncreaseDecreaseInInterestRateOrCurrencyRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percent of increase (decrease) in interest rate and currency rate that would have material effect of fair market value of portfolio.", "label": "Percentage of Increase (Decrease) in Interest Rate or Currency Rate", "terseLabel": "Increase in interest rate or currency rate" } } }, "localname": "PercentageOfIncreaseDecreaseInInterestRateOrCurrencyRate", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureFinancialInstrumentsRiskManagementAndCapitalManagementDetails" ], "xbrltype": "percentItemType" }, "lvtx_PrepaidProjectExpenses": { "auth_ref": [], "calculation": { "http://www.lavatherapeutics.com/role/DisclosureWorkingCapitalAccruedExpensesAndOtherCurrentLiabilitiesDetailss": { "order": 3.0, "parentTag": "ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for project expenses that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Project Expenses", "terseLabel": "Prepaid project expenses" } } }, "localname": "PrepaidProjectExpenses", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureWorkingCapitalPrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "lvtx_ProceedsFromIssueOfPreferenceSharesNetOfCostOfRepurchaseOfStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of preferred stock net of cost of repurchase of stock.", "label": "Proceeds from issue of preference shares, Net of Cost of Repurchase of Stock", "terseLabel": "Proceeds from issuance of shares net of cost of repurchase of stocks" } } }, "localname": "ProceedsFromIssueOfPreferenceSharesNetOfCostOfRepurchaseOfStock", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesPreferenceShareDetails" ], "xbrltype": "monetaryItemType" }, "lvtx_ProceedsFromIssueOfPreferenceSharesNetOfIssuanceCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of preferred stock net of issuance costs.", "label": "Proceeds from issue of preference shares, Net Of Issuance Costs", "terseLabel": "Proceeds from issuance of shares net of issuance costs" } } }, "localname": "ProceedsFromIssueOfPreferenceSharesNetOfIssuanceCosts", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesPreferenceShareDetails", "http://www.lavatherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "lvtx_ProportionOfEquityInterestHeld": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Proportion of equity interest held.", "label": "Proportion of Equity Interest Held", "terseLabel": "Percentage of equity interest" } } }, "localname": "ProportionOfEquityInterestHeld", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureCorporateAndCompanyInformationDetails" ], "xbrltype": "percentItemType" }, "lvtx_RedmileBiopharmaInvestmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Redmile Biopharma Investments.", "label": "Redmile Biopharma Investments [Member]", "terseLabel": "Redmile Biopharma Investments" } } }, "localname": "RedmileBiopharmaInvestmentsMember", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesMajorShareholdersDetails" ], "xbrltype": "domainItemType" }, "lvtx_RelatedPartyConsultancyFees": { "auth_ref": [], "calculation": { "http://www.lavatherapeutics.com/role/DisclosureRelatedPartiesDirectorAndShareholderCompensationDetails": { "order": 1.0, "parentTag": "ifrs-full_ServicesReceivedRelatedPartyTransactions", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses for related party consultancy fees.", "label": "Related Party, Consultancy Fees", "terseLabel": "Consultancy fees" } } }, "localname": "RelatedPartyConsultancyFees", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureRelatedPartiesDirectorAndShareholderCompensationDetails" ], "xbrltype": "monetaryItemType" }, "lvtx_ResearchAndDevelopmentExpenseFacilitiesAndOtherExpenses": { "auth_ref": [], "calculation": { "http://www.lavatherapeutics.com/role/DisclosureResearchAndDevelopmentExpensesDetails": { "order": 6.0, "parentTag": "ifrs-full_ResearchAndDevelopmentExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of facilities and other research and development expenses directly attributable to research or development activities, recognised in profit or loss.", "label": "Research And Development Expense, Facilities And Other Expenses", "terseLabel": "Facilities and other research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpenseFacilitiesAndOtherExpenses", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureResearchAndDevelopmentExpensesDetails" ], "xbrltype": "monetaryItemType" }, "lvtx_ResearchAndDevelopmentExpensePersonnelRelatedExpenses": { "auth_ref": [], "calculation": { "http://www.lavatherapeutics.com/role/DisclosureResearchAndDevelopmentExpensesDetails": { "order": 2.0, "parentTag": "ifrs-full_ResearchAndDevelopmentExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of personnel-related expenses directly attributable to research or development activities, recognised in profit or loss.", "label": "Research And Development Expense, Personnel Related Expenses", "terseLabel": "Personnel-related expenses" } } }, "localname": "ResearchAndDevelopmentExpensePersonnelRelatedExpenses", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureResearchAndDevelopmentExpensesDetails" ], "xbrltype": "monetaryItemType" }, "lvtx_ResearchAndDevelopmentExpensePreClinicalAndClinicalTrialExpenses": { "auth_ref": [], "calculation": { "http://www.lavatherapeutics.com/role/DisclosureResearchAndDevelopmentExpensesDetails": { "order": 3.0, "parentTag": "ifrs-full_ResearchAndDevelopmentExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of pre-clinical and clinical trial expenses directly attributable to research or development activities, recognised in profit or loss.", "label": "Research And Development Expense, Pre Clinical And Clinical Trial Expenses", "terseLabel": "Pre-clinical and clinical trial expenses" } } }, "localname": "ResearchAndDevelopmentExpensePreClinicalAndClinicalTrialExpenses", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureResearchAndDevelopmentExpensesDetails" ], "xbrltype": "monetaryItemType" }, "lvtx_ResearchAndDevelopmentExpenseResearchAndDevelopmentActivitiesExpenses": { "auth_ref": [], "calculation": { "http://www.lavatherapeutics.com/role/DisclosureResearchAndDevelopmentExpensesDetails": { "order": 4.0, "parentTag": "ifrs-full_ResearchAndDevelopmentExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of research and development activities expenses directly attributable to research or development activities, recognised in profit or loss.", "label": "Research And Development Expense, Research And Development Activities Expenses", "terseLabel": "Research and development activities expenses" } } }, "localname": "ResearchAndDevelopmentExpenseResearchAndDevelopmentActivitiesExpenses", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureResearchAndDevelopmentExpensesDetails" ], "xbrltype": "monetaryItemType" }, "lvtx_ResearchAndDevelopmentExpenseShareBasedCompensationExpense": { "auth_ref": [], "calculation": { "http://www.lavatherapeutics.com/role/DisclosureResearchAndDevelopmentExpensesDetails": { "order": 5.0, "parentTag": "ifrs-full_ResearchAndDevelopmentExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of share-based compensation expense directly attributable to research or development activities, recognised in profit or loss.", "label": "Research And Development Expense, Share Based Compensation Expense", "terseLabel": "Share-based compensation expense" } } }, "localname": "ResearchAndDevelopmentExpenseShareBasedCompensationExpense", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureResearchAndDevelopmentExpensesDetails" ], "xbrltype": "monetaryItemType" }, "lvtx_ResearchAndDevelopmentExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpensesAbstract", "nsuri": "http://www.lavatherapeutics.com/20211231", "xbrltype": "stringItemType" }, "lvtx_ResearchAndDevelopmentExternalProjectCostsCurrent": { "auth_ref": [], "calculation": { "http://www.lavatherapeutics.com/role/DisclosureWorkingCapitalAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": 2.0, "parentTag": "ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development external project costs.", "label": "Research and Development External Project Costs, Current", "terseLabel": "Research and development external project costs" } } }, "localname": "ResearchAndDevelopmentExternalProjectCostsCurrent", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureWorkingCapitalAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "lvtx_ResearchAndDevelopmentLicenseExpenses": { "auth_ref": [], "calculation": { "http://www.lavatherapeutics.com/role/DisclosureResearchAndDevelopmentExpensesDetails": { "order": 1.0, "parentTag": "ifrs-full_ResearchAndDevelopmentExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of license expenses directly attributable to research or development activities, recognised in profit or loss.", "label": "Research and development License Expenses", "terseLabel": "VUmc license expenses" } } }, "localname": "ResearchAndDevelopmentLicenseExpenses", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureResearchAndDevelopmentExpensesDetails" ], "xbrltype": "monetaryItemType" }, "lvtx_ResearchAndLicenseAgreementDevelopmentMilestonesPaymentReceived": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Development milestones payment received under research and license agreement.", "label": "Research And License Agreement, Development Milestones Payment Received", "terseLabel": "Development milestones payment received" } } }, "localname": "ResearchAndLicenseAgreementDevelopmentMilestonesPaymentReceived", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureRevenueDetails" ], "xbrltype": "monetaryItemType" }, "lvtx_ResearchAndLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for research and license agreement.", "label": "Research And License Agreement [Member]", "terseLabel": "Research and license agreement" } } }, "localname": "ResearchAndLicenseAgreementMember", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureRevenueDetails" ], "xbrltype": "domainItemType" }, "lvtx_ResearchAndLicenseAgreementNonRefundableUpfrontPaymentReceived": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Non-refundable upfront payment received under research and license agreement.", "label": "Research And License Agreement, Non Refundable Upfront Payment Received", "terseLabel": "Non-refundable upfront payment received" } } }, "localname": "ResearchAndLicenseAgreementNonRefundableUpfrontPaymentReceived", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureRevenueDetails" ], "xbrltype": "monetaryItemType" }, "lvtx_ResearchAndLicenseAgreementRevenueDevelopmentMilestones": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenue related to development milestones under research and license agreement.", "label": "Research And License Agreement, Revenue, Development Milestones", "terseLabel": "Revenue related to development milestones" } } }, "localname": "ResearchAndLicenseAgreementRevenueDevelopmentMilestones", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureRevenueDetails" ], "xbrltype": "monetaryItemType" }, "lvtx_ResearchAndLicenseAgreementRevenueUpfrontPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenue related to upfront payment under research and license agreement.", "label": "Research And License Agreement, Revenue, Upfront Payment", "terseLabel": "Revenue related to upfront payment" } } }, "localname": "ResearchAndLicenseAgreementRevenueUpfrontPayment", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureRevenueDetails" ], "xbrltype": "monetaryItemType" }, "lvtx_ResearchAndLicenseAgreementRoyaltiesPayableYearsOfSale": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Years of sale for royalties payable under research and license agreement.", "label": "Research And License Agreement, Royalties Payable , Years Of Sale", "terseLabel": "Years of sale for royalties payable" } } }, "localname": "ResearchAndLicenseAgreementRoyaltiesPayableYearsOfSale", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureRevenueDetails" ], "xbrltype": "durationItemType" }, "lvtx_ReserveOfEquitySettledEmployeeBenefits": { "auth_ref": [], "calculation": { "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPositions": { "order": 3.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "A component of equity representing the equity-settled employee benefits reserve.", "label": "Reserve Of Equity Settled Employee Benefits", "terseLabel": "Equity-settled employee benefits reserve" } } }, "localname": "ReserveOfEquitySettledEmployeeBenefits", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "lvtx_ReserveOfEquitySettledEmployeeBenefitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for a component of equity representing the accumulated equity-settled employee benefits reserve.", "label": "Equity-settled employee benefits reserve" } } }, "localname": "ReserveOfEquitySettledEmployeeBenefitsMember", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "lvtx_RightOfUseAssetsIncreaseDecreaseThroughNetExchangeDifferences": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in right-of-use assets resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity.", "label": "Right-of-Use Assets, Increase (Decrease) Through Net Exchange Differences", "terseLabel": "Foreign currency exchange difference" } } }, "localname": "RightOfUseAssetsIncreaseDecreaseThroughNetExchangeDifferences", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureLeasesDetails" ], "xbrltype": "monetaryItemType" }, "lvtx_SanofiForeignParticipationsB.v.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Sanofi Foreign Participations B.V.", "label": "Sanofi Foreign Participations B.V. [Member]", "terseLabel": "Sanofi Foreign Participations B.V." } } }, "localname": "SanofiForeignParticipationsB.v.Member", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesMajorShareholdersDetails" ], "xbrltype": "domainItemType" }, "lvtx_ScheduleOfAccruedExpensesAndOtherLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of accrued expenses and other current liabilities.", "label": "Schedule Of Accrued Expenses And Other Liabilities [Table Text Block]", "terseLabel": "Schedule of accrued expenses and other current liabilities" } } }, "localname": "ScheduleOfAccruedExpensesAndOtherLiabilitiesTableTextBlock", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureWorkingCapitalTables" ], "xbrltype": "textBlockItemType" }, "lvtx_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of general and administrative expenses.", "label": "Schedule of General And Administrative Expenses [Table Text Block]", "terseLabel": "Schedule of general and administrative expenses" } } }, "localname": "ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureGeneralAndAdministrativeExpensesTables" ], "xbrltype": "textBlockItemType" }, "lvtx_ScheduleOfMajorShareholdersOnNonDilutedBasisTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of major shareholders on a non-diluted basis.", "label": "Schedule of Major Shareholders on Non-diluted Basis [Table Text Block]", "terseLabel": "Schedule of major shareholders on a non-diluted basis" } } }, "localname": "ScheduleOfMajorShareholdersOnNonDilutedBasisTableTextBlock", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesTables" ], "xbrltype": "textBlockItemType" }, "lvtx_ScheduleOfResearchAndDevelopmentExpensesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of research and development expenses.", "label": "Schedule Of Research And Development Expenses [Table Text Block]", "terseLabel": "Schedule of research and development expenses" } } }, "localname": "ScheduleOfResearchAndDevelopmentExpensesTableTextBlock", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureResearchAndDevelopmentExpensesTables" ], "xbrltype": "textBlockItemType" }, "lvtx_SeriesBPreferenceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Series B preference share.", "label": "Series B Preference Shares" } } }, "localname": "SeriesBPreferenceSharesMember", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesPreferenceShareDetails", "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesSummaryDetails", "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "lvtx_SeriesCPreferenceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Series C preference share.", "label": "Series C Preference Shares" } } }, "localname": "SeriesCPreferenceSharesMember", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesPreferenceShareDetails", "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesSummaryDetails", "http://www.lavatherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity", "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquityParenthetical" ], "xbrltype": "domainItemType" }, "lvtx_SeriesPreferenceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Series A preference share.", "label": "Series A Preference Shares" } } }, "localname": "SeriesPreferenceSharesMember", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesPreferenceShareDetails", "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesSummaryDetails", "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "lvtx_ShareholdingPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shareholding percentage.", "label": "Shareholding Percentage", "terseLabel": "Shareholding percentage" } } }, "localname": "ShareholdingPercentage", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesMajorShareholdersDetails" ], "xbrltype": "percentItemType" }, "lvtx_SharesIssuedInLieuOfLicenseLiabilities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of license liability.", "label": "Shares Issued, In lieu of License Liabilities", "terseLabel": "Number of shares issued in lieu of license liability" } } }, "localname": "SharesIssuedInLieuOfLicenseLiabilities", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesCommonSharesDetails" ], "xbrltype": "sharesItemType" }, "lvtx_SharesIssuedInLieuOfLicenseLiability": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of license liability.", "label": "Shares Issued, In lieu of License Liability", "terseLabel": "Issuance of VUmc common stock (in shares)" } } }, "localname": "SharesIssuedInLieuOfLicenseLiability", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical", "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "sharesItemType" }, "lvtx_SignificantAccountingJudgmentsEstimatesAndAssumptionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Significant accounting judgments, estimates and assumptions" } } }, "localname": "SignificantAccountingJudgmentsEstimatesAndAssumptionsAbstract", "nsuri": "http://www.lavatherapeutics.com/20211231", "xbrltype": "stringItemType" }, "lvtx_StockIssuedDuringPeriodValueOfStockSplit": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of stock split.", "label": "Stock Issued During Period Value Of Stock Split", "negatedLabel": "Share split" } } }, "localname": "StockIssuedDuringPeriodValueOfStockSplit", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "lvtx_StockOptionPlan2018Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for 2018 stock option plan.", "label": "2018 Stock Option Plan" } } }, "localname": "StockOptionPlan2018Member", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationNumberOfOptionAndExercisePriceDetails" ], "xbrltype": "domainItemType" }, "lvtx_StockRepurchaseProgramAmountOfSharesRepurchased": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of shares to be repurchased by an entity's Board of Directors under a stock repurchase plan.", "label": "Stock Repurchase Program, Amount of Shares Repurchased", "terseLabel": "Amount of shares obliged to repurchase" } } }, "localname": "StockRepurchaseProgramAmountOfSharesRepurchased", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesPreferenceShareDetails" ], "xbrltype": "monetaryItemType" }, "lvtx_StockRepurchaseProgramNumberOfSharesRepurchased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares to be repurchased by an entity's Board of Directors under a stock repurchase plan.", "label": "Stock Repurchase Program, Number of Shares Repurchased", "terseLabel": "Number of shares obliged to repurchase" } } }, "localname": "StockRepurchaseProgramNumberOfSharesRepurchased", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesPreferenceShareDetails" ], "xbrltype": "sharesItemType" }, "lvtx_StockSplitConversionRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.", "label": "Stock Split, Conversion Ratio", "terseLabel": "Share split, conversion ratio" } } }, "localname": "StockSplitConversionRatio", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesPreferenceShareDetails" ], "xbrltype": "pureItemType" }, "lvtx_SummaryOfSignificantAccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Summary of significant accounting policies" } } }, "localname": "SummaryOfSignificantAccountingPoliciesAbstract", "nsuri": "http://www.lavatherapeutics.com/20211231", "xbrltype": "stringItemType" }, "lvtx_SupplementalScheduleOfNoncashInvestingAndFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Supplemental schedule of noncash operating and financing activities:" } } }, "localname": "SupplementalScheduleOfNoncashInvestingAndFinancingActivitiesAbstract", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "lvtx_TaxPeriod2017Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for tax period 2017.", "label": "2017" } } }, "localname": "TaxPeriod2017Member", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureTaxationTaxLossesCarryForwardDetails" ], "xbrltype": "domainItemType" }, "lvtx_TaxPeriod2018Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for tax period 2018.", "label": "2018" } } }, "localname": "TaxPeriod2018Member", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureTaxationTaxLossesCarryForwardDetails" ], "xbrltype": "domainItemType" }, "lvtx_TaxPeriod2019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for tax period 2019.", "label": "2019" } } }, "localname": "TaxPeriod2019Member", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureTaxationTaxLossesCarryForwardDetails" ], "xbrltype": "domainItemType" }, "lvtx_TaxPeriod2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tax Period 2021 [Member]", "label": "2021" } } }, "localname": "TaxPeriod2021Member", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureTaxationTaxLossesCarryForwardDetails" ], "xbrltype": "domainItemType" }, "lvtx_TaxableIncomeExpenseInnovationBoxTaxLaw": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of taxable income (expenses) declared in the tax returns files per innovation box tax scheme.", "label": "Taxable Income Expense, Innovation Box Tax Law", "terseLabel": "Amount of tax returns" } } }, "localname": "TaxableIncomeExpenseInnovationBoxTaxLaw", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureTaxationTaxLossesCarryForwardDetails" ], "xbrltype": "monetaryItemType" }, "lvtx_TermOfResearchAndLicenseAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term of agreement over which upfront payment received are recognized on a straight-line basis.", "label": "Term Of Research And License Agreement", "terseLabel": "Term of agreement" } } }, "localname": "TermOfResearchAndLicenseAgreement", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureRevenueDetails", "http://www.lavatherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "durationItemType" }, "lvtx_TradeAndOtherPayablesLineItem": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represents trade payables.", "label": "Trade and Other Payables [Line Item]" } } }, "localname": "TradeAndOtherPayablesLineItem", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureTradePayablesAndOtherDetails" ], "xbrltype": "stringItemType" }, "lvtx_TradePayablesAndOtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for trade payables and other.", "label": "Trade payables and other" } } }, "localname": "TradePayablesAndOtherMember", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureFinancialInstrumentsRiskManagementAndCapitalManagementDetails" ], "xbrltype": "domainItemType" }, "lvtx_TradePayablesAndOtherTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Hypercube table represents trade payable", "label": "Trade Payables And Other [Table]" } } }, "localname": "TradePayablesAndOtherTable", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureTradePayablesAndOtherDetails" ], "xbrltype": "stringItemType" }, "lvtx_TradeReceivablesAndOtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for trade receivables and other.", "label": "Receivables and other" } } }, "localname": "TradeReceivablesAndOtherMember", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureFinancialInstrumentsRiskManagementAndCapitalManagementDetails" ], "xbrltype": "domainItemType" }, "lvtx_TrancheOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for tranche one.", "label": "Tranche one" } } }, "localname": "TrancheOneMember", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesPreferenceShareDetails" ], "xbrltype": "domainItemType" }, "lvtx_TrancheTwoAndThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for tranche two and three.", "label": "Tranche two and three" } } }, "localname": "TrancheTwoAndThreeMember", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesPreferenceShareDetails" ], "xbrltype": "domainItemType" }, "lvtx_U.s.StockOptionPlan2020Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for 2020 U.S. stock option plan.", "label": "2020 U.S. Stock Option Plan," } } }, "localname": "U.s.StockOptionPlan2020Member", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationNumberOfOptionAndExercisePriceDetails" ], "xbrltype": "domainItemType" }, "lvtx_UnderwritersDiscountAndCommission": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses for underwriters discount and commission.", "label": "Underwriters Discount And Commission", "terseLabel": "Underwriters discount and commission" } } }, "localname": "UnderwritersDiscountAndCommission", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesCommonSharesDetails" ], "xbrltype": "monetaryItemType" }, "lvtx_UndiscountedLeaseLiabilityPaymentsDue": { "auth_ref": [], "calculation": { "http://www.lavatherapeutics.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments.", "label": "Undiscounted Lease Liability, Payments, Due", "terseLabel": "Total lease commitments" } } }, "localname": "UndiscountedLeaseLiabilityPaymentsDue", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "lvtx_UnusedTaxLossesIpDevelopmentCostActivatedInnovationBoxTaxLaw": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of unused tax losses for IP development cost activated per innovation box tax scheme available to be offset against future income.", "label": "Unused Tax Losses, IP Development Cost Activated, Innovation Box Tax Law", "terseLabel": "IP development costs" } } }, "localname": "UnusedTaxLossesIpDevelopmentCostActivatedInnovationBoxTaxLaw", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureTaxationTaxLossesCarryForwardDetails" ], "xbrltype": "monetaryItemType" }, "lvtx_VersantVenturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Versant Ventures.", "label": "Versant Ventures [Member]", "terseLabel": "Versant Ventures" } } }, "localname": "VersantVenturesMember", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesMajorShareholdersDetails" ], "xbrltype": "domainItemType" }, "lvtx_WorkingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "n/a", "label": "Working capital" } } }, "localname": "WorkingCapitalAbstract", "nsuri": "http://www.lavatherapeutics.com/20211231", "xbrltype": "stringItemType" }, "lvtx_WorkingCapitalTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for working capital.", "label": "Working Capital [Text Block]", "terseLabel": "Working capital" } } }, "localname": "WorkingCapitalTextBlock", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureWorkingCapital" ], "xbrltype": "textBlockItemType" }, "lvtx_YsiosCapitalPartnersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Ysios Capital Partners, SGECR,S.A.U.", "label": "Ysios Capital Partners, SGECR,S.A.U." } } }, "localname": "YsiosCapitalPartnersMember", "nsuri": "http://www.lavatherapeutics.com/20211231", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareCapitalSharePremiumAndOtherCapitalReservesMajorShareholdersDetails" ], "xbrltype": "domainItemType" }, "srt_DirectorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Director" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationNarrativesDetails" ], "xbrltype": "domainItemType" }, "srt_OfficerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Employee and Non-employee" } } }, "localname": "OfficerMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationNarrativesDetails" ], "xbrltype": "domainItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationNarrativesDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.lavatherapeutics.com/role/DisclosureShareBasedCompensationNarrativesDetails" ], "xbrltype": "domainItemType" } }, "unitCount": 9 } }, "std_ref": { "r0": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_a&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d_i&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r10": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "k", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_k&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r100": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r101": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "f", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_f&doctype=Appendix&subtype=B", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r102": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "g", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r103": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B4", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r104": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Section": "Nature of the risks associated with an entity's interests in consolidated structured entities", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS12_g14-17_TI", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r105": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_a&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r106": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_b&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_e&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "14", "Paragraph": "33", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2021-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "55", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_55&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r110": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Paragraph": "105", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_105&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Paragraph": "113", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_113_a&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Paragraph": "114", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_114&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Paragraph": "116", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_116_a&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Paragraph": "118", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_118&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Paragraph": "120", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_120_b_i&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS15_g110-129_TI", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Section": "Presentation", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS15_g105-109_TI", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "47", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_a&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "61", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_61_a&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r120": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_b&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "g", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_g&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "h", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_h&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "j", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_j&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "53", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "94", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_94&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "97", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_97&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "C12", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_C12_a&doctype=Appendix&subtype=C", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS16_g51-60_TI", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Section": "Presentation", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS16_g47-50_TI", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "61", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_61&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r130": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "44", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_44&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_i&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_ii&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Clause": "iv", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_iv&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Clause": "vi", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_vi&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Clause": "vii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_vii&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_c&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_d&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "66", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_66&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r140": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "47", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_47_a_i&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "47", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_47_a&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "51", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_51_a&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "3", "Paragraph": "B67", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "5", "Paragraph": "33", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2021-en-r&anchor=para_33_b_i&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "21C", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_21C&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "23B", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_23B_a&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "25", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_25&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "31", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_31&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "33", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_33&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "69", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_69&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r150": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "34", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_34&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "35H", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35H&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "35I", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35I&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "35K", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35K&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "35M", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35M&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "42E", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_42E_e&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "42I", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_42I&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "6", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_6&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "7", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_7&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "8", "Subparagraph": "f", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_8_f&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "7", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_7&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r160": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "8", "Subparagraph": "g", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_8_g&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "8", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_8&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "B52", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B52&doctype=Appendix&subtype=B", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Section": "Scope", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "23", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23_d&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "23", "Subparagraph": "h", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23_h&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "23", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_c&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_d&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r170": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_e&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "33", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_33&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "9", "Paragraph": "7.2.34", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2021-en-r&anchor=para_7.2.34&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "109", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_109&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "109A", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_109A&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "120", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_120&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "124", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_124&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "125", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_125&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "127", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_127&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "128", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_128_a_ii&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_d&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r180": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "128", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_128_a&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "132", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_132_b&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "C32", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_C32&doctype=Appendix&subtype=C", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "9", "Paragraph": "7.2.42", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2021-en-r&anchor=para_7.2.42&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective on first application of IFRS 9", "Number": "4", "Paragraph": "39L", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2021-en-b&anchor=para_39L_b&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "8", "Subparagraph": "f", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_8_f&doctype=Standard&book=b", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "102", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_102&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r187": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "103", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_103&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r188": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "108", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_108&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r189": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r19": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r190": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "IG6", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_IG6&doctype=Implementation%20Guidance", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r191": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "37", "Subparagraph": "h", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_37_h&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r192": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "19", "Paragraph": "138", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_138_a&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r193": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "19", "Paragraph": "147", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_147_c&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r194": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "21", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_21_c&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r195": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "32", "Paragraph": "IE33", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=32&code=ifrs-tx-2021-en-r&anchor=para_IE33&doctype=Illustrative%20Examples", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r196": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "36", "Paragraph": "127", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2021-en-r&anchor=para_127&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r197": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "16", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_16_a&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r198": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "17", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17_b&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r199": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "17", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17_c&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r2": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d_iii&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r20": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a_i&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r200": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "17", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r201": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "44C", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_44C&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r202": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Section": "A Statement of cash flows for an entity other than a financial institution", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A__IAS07_IE_A_TI", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r203": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Section": "C Reconciliation of liabilities arising from financing activities", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_C__IAS07_IE_C_TI", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r204": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B10", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r205": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "94", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_94&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r206": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "B6", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_B6&doctype=Appendix&subtype=B", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r207": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "IE60", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_IE60&doctype=Illustrative%20Examples", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r208": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "IE63", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_IE63&doctype=Illustrative%20Examples", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r209": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Paragraph": "118", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_118_b&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r21": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a_ii&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r210": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Paragraph": "118", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r211": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Paragraph": "B89", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r212": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "53", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r213": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "32", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_32&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r214": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "35N", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35N&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r215": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "B11", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B11&doctype=Appendix&subtype=B", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r216": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "B35", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B35&doctype=Appendix&subtype=B", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r217": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "IG31A", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r218": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "23", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r219": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r22": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a_iii&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r220": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "113", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r221": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "96", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_96_b&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r222": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective on first application of IFRS 9", "Number": "4", "Paragraph": "39L", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2021-en-b&anchor=para_39L_e&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r223": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "37", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37_b&doctype=Standard&book=b", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r224": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "IG29", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29_a&doctype=Implementation%20Guidance&book=b", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r225": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r226": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r227": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r228": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r229": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r23": { "Clause": "iv", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a_iv&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r230": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r231": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r232": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r233": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r234": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r235": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r236": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "10", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_10_e&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r237": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r238": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "108", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_108&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r239": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "112", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_112_c&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r24": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r240": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "117", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_117_b&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r241": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "35", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_35&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r242": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "55", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_55&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r243": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r244": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r245": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "85", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_85&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r246": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "37", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_37&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r247": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "21", "Paragraph": "52", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=21&code=ifrs-tx-2021-en-r&anchor=para_52_a&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r248": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "17", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r249": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "20", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20_a&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r25": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r250": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "20", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20_b&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r251": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "20", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r252": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "45", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_45&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r253": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "7", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_7&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r254": { "IssueDate": "2021-01-01", "Name": "IAS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "16", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2017-en-b&anchor=para_16&doctype=Standard&book=b", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r255": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "37", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37_b&doctype=Standard&book=b", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r256": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "IG29", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29&doctype=Implementation%20Guidance&book=b", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r26": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "81A", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81A_a&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "81A", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81A_c&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "82", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82_d&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "91", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_91_a&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r30": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Paragraph": "79", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_79&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_c_i&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_c_ii&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_e&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "g", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_g_i&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "g", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_g&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_c&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e_i&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "117", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_117&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r40": { "Clause": "vii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e_vii&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Clause": "viii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e_viii&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "73", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "75", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_75_a&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "75", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_75_b&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS16_g73-79_TI", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "21", "Paragraph": "52", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=21&code=ifrs-tx-2021-en-r&anchor=para_52_a&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "21", "Paragraph": "52", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=21&code=ifrs-tx-2021-en-r&anchor=para_52_b&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "21", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=21&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS21_g51-57_TI", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "35", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_35&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r50": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "23", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=23&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS23_g26-26_TI", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "17", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "17", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_17_b&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "17", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "17", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_17&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "18", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r56": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "18", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_18&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r57": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "19", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_19&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r58": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "20", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_20&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r59": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Section": "Disclosures", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r6": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "51", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_51&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r60": { "Clause": "viii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "26", "Paragraph": "35", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=26&code=ifrs-tx-2021-en-r&anchor=para_35_b_viii&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r61": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "27", "Paragraph": "16", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2021-en-r&anchor=para_16_b_iii&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r62": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "27", "Paragraph": "16", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2021-en-r&anchor=para_16_b&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r63": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "27", "Paragraph": "17", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2021-en-r&anchor=para_17_b_iii&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r64": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "27", "Paragraph": "17", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2021-en-r&anchor=para_17_b&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r65": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "33", "Paragraph": "66", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_66&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r66": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "33", "Paragraph": "67", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_67&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r67": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "33", "Paragraph": "70", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r68": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "33", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r69": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "36", "Paragraph": "126", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2021-en-r&anchor=para_126&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r7": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_a&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r70": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "36", "Paragraph": "130", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2021-en-r&anchor=para_130_d_ii&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r71": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "37", "Paragraph": "86", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=37&code=ifrs-tx-2021-en-r&anchor=para_86&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r72": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r73": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r74": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Paragraph": "126", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_126&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r75": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "40", "Paragraph": "32A", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=40&code=ifrs-tx-2021-en-r&anchor=para_32A&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r76": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "40", "Paragraph": "76", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=40&code=ifrs-tx-2021-en-r&anchor=para_76&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r77": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "40", "Paragraph": "79", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=40&code=ifrs-tx-2021-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r78": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "40", "Paragraph": "79", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=40&code=ifrs-tx-2021-en-r&anchor=para_79_d&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r79": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "41", "Paragraph": "50", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=41&code=ifrs-tx-2021-en-r&anchor=para_50&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r8": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "h", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_h&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r80": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "41", "Paragraph": "54", "Subparagraph": "f", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=41&code=ifrs-tx-2021-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r81": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "10", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_10&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r82": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "18", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r83": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "25", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_25&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r84": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "28", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_28&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r85": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "35", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r86": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "45", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_45&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r87": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "46", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_46&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r88": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "50", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_50_d&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r89": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Section": "Presentation of a statement of cash flows", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS07_g10-17_TI", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r9": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "i", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_i&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r90": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "24", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r91": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "24", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r92": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "32", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_32_a_i&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r93": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "32", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_32_a_ii&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r94": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "19B", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_19B_c&doctype=Standard", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r95": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r96": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r97": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r98": { "Clause": "iv", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r99": { "Clause": "ix", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B", "URIDate": "2021-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" } }, "version": "2.2" }